<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>LOVENOX- enoxaparin sodium injection </strong><br>sanofi-aventis U.S. LLC<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use Lovenox safely and effectively. See full prescribing information for Lovenox.<br><br> Lovenox (enoxaparin sodium injection) for subcutaneous and intravenous use<br> Initial U.S. Approval: 1993</div>
<div class="Warning"><div>
<h1 class="Warning">
<span class="Bold">WARNING</span>: <span class="Bold">SPINAL/<span class="product-label-link" type="condition" conceptid="4176148" conceptname="Extradural intracranial hematoma">EPIDURAL HEMATOMA</span></span>
</h1>
<h1 class="Warning"><span class="Bold Italics">See full prescribing information for complete boxed warning.</span></h1>
<p class="Highlighta"><span class="Bold">Epidural or spinal <span class="product-label-link" type="condition" conceptid="4147001" conceptname="Hematoma">hematomas</span> may occur in patients who are anticoagulated with low molecular weight heparins (LMWH) or heparinoids and are receiving neuraxial anesthesia or undergoing spinal puncture. These <span class="product-label-link" type="condition" conceptid="4147001" conceptname="Hematoma">hematomas</span> may result in long-term or permanent <span class="product-label-link" type="condition" conceptid="440377" conceptname="Paralysis">paralysis</span>. Consider these risks when scheduling patients for spinal procedures. Factors that can increase the risk of developing epidural or spinal <span class="product-label-link" type="condition" conceptid="4147001" conceptname="Hematoma">hematomas</span> in these patients include:</span> </p>
<ul class="Disc">
<li><span class="Bold">Use of indwelling epidural catheters</span></li>
<li><span class="Bold">Concomitant use of other drugs that affect hemostasis, such as       non-steroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors,       other anticoagulants</span></li>
<li><span class="Bold">A history of traumatic or repeated epidural or spinal punctures</span></li>
<li><span class="Bold">A history of <span class="product-label-link" type="condition" conceptid="73302" conceptname="Curvature of spine">spinal deformity</span> or spinal surgery</span></li>
<li><span class="Bold">Optimal timing between the administration of Lovenox and neuraxial procedures is not known.</span></li>
</ul>
<p class="Highlighta"><span class="Bold">Monitor patients frequently for signs and symptoms of neurological impairment. If neurological compromise is noted, urgent treatment is necessary [see <span class="Italics"><a href="#S5.1">Warnings and Precautions (5.1)</a></span> and <span class="Italics"><a href="#S7">Drug Interactions (7)</a></span>].</span> </p>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div><table width="100%">
<col align="left" valign="top" width="75%">
<col align="right" valign="top" width="25%">
<tbody class="Headless">
<tr>
<td align="left"><a href="#BOX">Boxed Warning</a></td>
<td align="right">10/13</td>
</tr>
<tr>
<td align="left">Warnings and Precautions (<span class="Italics"><a href="#S5.1">5.1</a></span>)</td>
<td align="right">10/13</td>
</tr>
</tbody>
</table></div>
</div>
<div></div>
<div class="Warning"><div>
<h1 class="Warning">
<span class="Bold">WARNING</span>: <span class="Bold">SPINAL/<span class="product-label-link" type="condition" conceptid="4176148" conceptname="Extradural intracranial hematoma">EPIDURAL HEMATOMA</span></span>
</h1>
<h1 class="Warning"><span class="Bold Italics">See full prescribing information for complete boxed warning.</span></h1>
<p class="Highlighta"><span class="Bold">Epidural or spinal <span class="product-label-link" type="condition" conceptid="4147001" conceptname="Hematoma">hematomas</span> may occur in patients who are anticoagulated with low molecular weight heparins (LMWH) or heparinoids and are receiving neuraxial anesthesia or undergoing spinal puncture. These <span class="product-label-link" type="condition" conceptid="4147001" conceptname="Hematoma">hematomas</span> may result in long-term or permanent <span class="product-label-link" type="condition" conceptid="440377" conceptname="Paralysis">paralysis</span>. Consider these risks when scheduling patients for spinal procedures. Factors that can increase the risk of developing epidural or spinal <span class="product-label-link" type="condition" conceptid="4147001" conceptname="Hematoma">hematomas</span> in these patients include:</span> </p>
<ul class="Disc">
<li><span class="Bold">Use of indwelling epidural catheters</span></li>
<li><span class="Bold">Concomitant use of other drugs that affect hemostasis, such as       non-steroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors,       other anticoagulants</span></li>
<li><span class="Bold">A history of traumatic or repeated epidural or spinal punctures</span></li>
<li><span class="Bold">A history of <span class="product-label-link" type="condition" conceptid="73302" conceptname="Curvature of spine">spinal deformity</span> or spinal surgery</span></li>
<li><span class="Bold">Optimal timing between the administration of Lovenox and neuraxial procedures is not known.</span></li>
</ul>
<p class="Highlighta"><span class="Bold">Monitor patients frequently for signs and symptoms of neurological impairment. If neurological compromise is noted, urgent treatment is necessary [see <span class="Italics"><a href="#S5.1">Warnings and Precautions (5.1)</a></span> and <span class="Italics"><a href="#S7">Drug Interactions (7)</a></span>].</span> </p>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">Lovenox is a low molecular weight heparin [LMWH] indicated for: </p>
<ul>
<li> Prophylaxis of <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">deep vein thrombosis</span> (DVT) in abdominal surgery, hip replacement surgery, knee replacement surgery, or medical patients with severely restricted mobility during acute illness (<a href="#S1.1">1.1</a>)</li>
<li> Inpatient treatment of acute DVT with or without <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span> (<a href="#S1.2">1.2</a>)</li>
<li> Outpatient treatment of acute DVT without <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span>. (<a href="#S1.2">1.2</a>)</li>
<li> Prophylaxis of ischemic complications of <span class="product-label-link" type="condition" conceptid="315296" conceptname="Preinfarction syndrome">unstable angina</span> and non-Q-wave <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> [MI] (<a href="#S1.3">1.3</a>)</li>
<li> Treatment of acute ST-segment elevation <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> [<span class="product-label-link" type="condition" conceptid="312327" conceptname="Acute myocardial infarction">STEMI</span>] managed medically or with subsequent percutaneous coronary intervention [PCI] (<a href="#S1.4">1.4</a>)</li>
</ul>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><table width="100%">
<col align="left" valign="top" width="50%">
<col align="left" valign="top" width="50%">
<thead><tr class="First Last">
<th class="Rrule" align="left">Indication</th>
<th align="left">Dose</th>
</tr></thead>
<tfoot>
<tr class="Botrule First Last"><td align="left" colspan="2"><ul class="Disc">
<li>See recommended durations for Lovenox therapy (<a href="#S2.1">2.1</a>)</li>
<li>Adjust the dose for patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (<a href="#S2.2">2.2</a>,<a href="#S8.7"> 8.7</a>)</li>
</ul></td></tr>
<tr><td colspan="2" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>See recommendations regarding transitioning to warfarin therapy (<a href="#S2.1">2.1</a>)</dd>
</dl></td></tr>
</tfoot>
<tbody>
<tr class="Botrule First">
<td class="Rrule" align="left">DVT prophylaxis in abdominal surgery</td>
<td align="left">40 mg SC once daily </td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left">DVT prophylaxis in knee replacement surgery</td>
<td align="left">30 mg SC every 12 hours </td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left">DVT prophylaxis in hip replacement surgery</td>
<td align="left">30 mg SC every 12 hours or 40 mg SC once daily </td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left">DVT prophylaxis in medical patients</td>
<td align="left">40 mg SC once daily </td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left">Inpatient treatment of acute DVT with or without <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span></td>
<td align="left">1 mg/kg SC every 12 hours or 1.5 mg/kg SC once daily<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a>
</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left">Outpatient treatment of acute DVT without <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span></td>
<td align="left">1 mg/kg SC every 12 hours<a href="#footnote-1" class="Sup">*</a>
</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="315296" conceptname="Preinfarction syndrome">Unstable angina</span> and non-Q-wave MI</td>
<td align="left">1 mg/kg SC every 12 hours (with aspirin)  </td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left">Acute <span class="product-label-link" type="condition" conceptid="312327" conceptname="Acute myocardial infarction">STEMI</span> in patients &lt;75 years of age<br>[For dosing  in subsequent PCI, see<span class="Italics"><a href="#S2.1"> Dosage and Administration (2.1)</a></span>]</td>
<td align="left">30 mg single IV bolus plus a 1 mg/kg SC dose followed by 1 mg/kg SC every 12 hours (with aspirin)</td>
</tr>
<tr class="Last">
<td class="Rrule" align="left">Acute <span class="product-label-link" type="condition" conceptid="312327" conceptname="Acute myocardial infarction">STEMI</span> in patients ≥75 years of age</td>
<td align="left">0.75 mg/kg SC every 12 hours (no bolus) (with aspirin)</td>
</tr>
</tbody>
</table></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div>
<p class="Highlighta">100 mg/mL concentration (<a href="#S3.1">3.1</a>): </p>
<ul>
<li> Prefilled syringes: 30 mg/0.3 mL, 40 mg/0.4 mL</li>
<li> Graduated prefilled syringes: 60 mg/0.6 mL, 80 mg/0.8 mL,100 mg/1 mL</li>
<li> Multiple-dose vial: 300 mg/3 mL</li>
</ul>
<p class="Highlighta">150 mg/mL concentration (<a href="#S3.2">3.2</a>): </p>
<ul class="Disc"><li>Graduated prefilled syringes: 120 mg/0.8 mL, 150 mg/1 mL</li></ul>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul>
<li> Active major <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> (<a href="#S4">4</a>)</li>
<li> <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span> with a positive <span class="Italics">in vitro</span> test for anti-platelet antibody in the presence of enoxaparin sodium (<a href="#S4">4</a>)</li>
<li> <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to enoxaparin sodium (<a href="#S4">4</a>)</li>
<li> <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to heparin or pork products (<a href="#S4">4</a>)</li>
<li> <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to benzyl alcohol [for multi-dose formulation only] (<a href="#S4">4</a>)</li>
</ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul>
<li> Increased risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>: Use with caution in patients at risk (<a href="#S5.1">5.1</a>)</li>
<li> Percutaneous coronary revascularization: Obtain hemostasis at the puncture site before sheath removal (<a href="#S5.2">5.2</a>)</li>
<li> Concomitant medical conditions: Use with caution in patients with <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> diathesis, uncontrolled arterial <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> or history of recent gastrointestinal ulceration, <span class="product-label-link" type="condition" conceptid="4174977" conceptname="Diabetic retinopathy">diabetic retinopathy</span>, renal dysfunction, or <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span> (<a href="#S5.3">5.3</a>)</li>
<li> History of <span class="product-label-link" type="condition" conceptid="433749" conceptname="Heparin-induced thrombocytopenia">heparin-induced thrombocytopenia</span>: Use with caution (<a href="#S5.4">5.4</a>)</li>
<li> <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span>: Monitor <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> closely (<a href="#S5.5">5.5</a>)</li>
<li> Interchangeability with other heparins: Do not exchange with heparin or other LMWHs (<a href="#S5.6">5.6</a>)</li>
<li> Pregnant women with mechanical prosthetic heart valves and their fetuses, may be at increased risk and may need more frequent monitoring and dosage adjustment (<a href="#S5.7">5.7</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">Most common adverse reactions (&gt;1%) were <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, elevation of serum aminotransferase, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, and <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (<a href="#S6.1">6.1</a>) </p>
<br><p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact sanofi-aventis at 1-800-633-1610 or FDA at 1-800-FDA-1088 or <span class="Italics">www.fda.gov/medwatch.</span></span> </p>
</div>
<div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
</div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><p class="Highlighta">Discontinue agents which may enhance <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span> risk prior to initiation of Lovenox or conduct close clinical and laboratory monitoring (<a href="#S5.9">5.9</a>,<a href="#S7"> 7</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><ul>
<li>Severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>: Adjust dose for patients with creatinine clearance &lt;30mL/min (<a href="#S2.2">2.2</a>,<a href="#S8.7"> 8.7</a>)</li>
<li>Geriatric Patients: Monitor for increased risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> (<a href="#S8.5">8.5</a>)</li>
<li>Patients with mechanical heart valves: Not adequately studied (<a href="#S8.6">8.6</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span>: Use with caution. (<a href="#S8.8">8.8</a>)</li>
<li>Low-Weight Patients: Observe for signs of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> (<a href="#S8.9">8.9</a>)</li>
<li>Obese Patients: Not adequately studied. Observe for <span class="product-label-link" type="condition" conceptid="4159647" conceptname="Thromboembolic disorder">thromboembolism</span> (<a href="#S8.10">8.10</a>)</li>
</ul></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
</div>
</div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 6/2013</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc"><span class="Emphasis">WARNING: SPINAL/<span class="product-label-link" type="condition" conceptid="4176148" conceptname="Extradural intracranial hematoma">EPIDURAL HEMATOMAS</span></span></a></h1>
<h1><a href="#section-1" class="toc">1	INDICATIONS AND USAGE</a></h1>
<h2><a href="#section-1.1" class="toc">1.1 Prophylaxis of <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">Deep Vein Thrombosis</span></a></h2>
<h2><a href="#section-1.2" class="toc">1.2 Treatment of Acute <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">Deep Vein Thrombosis</span> </a></h2>
<h2><a href="#section-1.3" class="toc">1.3 Prophylaxis of Ischemic Complications of <span class="product-label-link" type="condition" conceptid="315296" conceptname="Preinfarction syndrome">Unstable Angina</span> and Non-Q-Wave <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Myocardial Infarction</span></a></h2>
<h2><a href="#section-1.4" class="toc">1.4 Treatment of Acute ST-Segment Elevation <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Myocardial Infarction</span></a></h2>
<h1><a href="#section-2" class="toc">2	DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 Adult Dosage</a></h2>
<h2><a href="#section-2.2" class="toc">2.2 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h2><a href="#section-2.3" class="toc">2.3 Geriatric Patients  with Acute ST-Segment Elevation <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Myocardial Infarction</span></a></h2>
<h2><a href="#section-2.4" class="toc">2.4 Administration</a></h2>
<h1><a href="#section-3" class="toc">3	DOSAGE FORMS AND STRENGTHS</a></h1>
<h2><a href="#section-3.1" class="toc">3.1 100 mg/mL Concentration</a></h2>
<h2><a href="#section-3.2" class="toc">3.2 150  mg/mL Concentration</a></h2>
<h1><a href="#section-4" class="toc">4	CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5	WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 Increased Risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Hemorrhage</span></a></h2>
<h2><a href="#section-5.2" class="toc">5.2 Percutaneous Coronary Revascularization Procedures</a></h2>
<h2><a href="#section-5.3" class="toc">5.3 Use of Lovenox with Concomitant Medical Conditions</a></h2>
<h2><a href="#section-5.4" class="toc">5.4 History of <span class="product-label-link" type="condition" conceptid="433749" conceptname="Heparin-induced thrombocytopenia">Heparin-Induced Thrombocytopenia</span></a></h2>
<h2><a href="#section-5.5" class="toc">5.5 <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span></a></h2>
<h2><a href="#section-5.6" class="toc">5.6 Interchangeability with Other Heparins</a></h2>
<h2><a href="#section-5.7" class="toc">5.7 Pregnant Women with Mechanical Prosthetic Heart Valves</a></h2>
<h2><a href="#section-5.8" class="toc">5.8 Benzyl Alcohol</a></h2>
<h2><a href="#section-5.9" class="toc">5.9 Laboratory Tests</a></h2>
<h1><a href="#section-6" class="toc">6	ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trials Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Postmarketing Experience </a></h2>
<h1><a href="#section-7" class="toc">7	DRUG INTERACTIONS</a></h1>
<h1><a href="#section-8" class="toc">8	USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.6 Patients with Mechanical Prosthetic Heart Valves</a></h2>
<h2><a href="#section-8.6" class="toc">8.7 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h2><a href="#section-8.7" class="toc">8.8 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h2><a href="#section-8.8" class="toc">8.9 Low-Weight Patients</a></h2>
<h2><a href="#section-8.9" class="toc">8.10 Obese Patients</a></h2>
<h1><a href="#section-9" class="toc">10	OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11	DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12	CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.2 Pharmacodynamics</a></h2>
<h2><a href="#section-11.3" class="toc">12.3 Pharmacokinetics </a></h2>
<h1><a href="#section-12" class="toc">13	NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h2><a href="#section-12.2" class="toc">13.2 Animal Toxicology and/or Pharmacology</a></h2>
<h2><a href="#section-12.3" class="toc">13.3 Reproductive and Developmental Toxicology</a></h2>
<h1><a href="#section-13" class="toc">14	CLINICAL STUDIES</a></h1>
<h2><a href="#section-13.1" class="toc">14.1 Prophylaxis of <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">Deep Vein Thrombosis</span> Following Abdominal Surgery in Patients at Risk for Thromboembolic Complications</a></h2>
<h2><a href="#section-13.2" class="toc">14.2 Prophylaxis of <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">Deep Vein Thrombosis</span> Following Hip or Knee Replacement Surgery</a></h2>
<h2><a href="#section-13.3" class="toc">14.3 Prophylaxis of <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">Deep Vein Thrombosis</span> in Medical Patients with Severely Restricted Mobility During Acute Illness </a></h2>
<h2><a href="#section-13.4" class="toc">14.4 Treatment of <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">Deep Vein Thrombosis</span> with or without <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">Pulmonary Embolism</span> </a></h2>
<h2><a href="#section-13.5" class="toc">14.5 Prophylaxis of Ischemic Complications in <span class="product-label-link" type="condition" conceptid="315296" conceptname="Preinfarction syndrome">Unstable Angina</span> and Non-Q-Wave <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Myocardial Infarction</span> </a></h2>
<h2><a href="#section-13.6" class="toc">14.6 Treatment of Acute ST-Segment Elevation <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Myocardial Infarction</span></a></h2>
<h1><a href="#section-14" class="toc">16	HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-15" class="toc">17	PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="DLDE"></a><a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="BOX"></a><a name="section-1"></a><p></p>
<h1><span class="Emphasis">WARNING: SPINAL/<span class="product-label-link" type="condition" conceptid="4176148" conceptname="Extradural intracranial hematoma">EPIDURAL HEMATOMAS</span></span></h1>
<p class="First"><span class="Bold">Epidural or spinal <span class="product-label-link" type="condition" conceptid="4147001" conceptname="Hematoma">hematomas</span> may occur in patients who are anticoagulated with low molecular weight heparins (LMWH) or heparinoids and are receiving neuraxial anesthesia or undergoing spinal puncture. These <span class="product-label-link" type="condition" conceptid="4147001" conceptname="Hematoma">hematomas</span> may result in long-term or permanent <span class="product-label-link" type="condition" conceptid="440377" conceptname="Paralysis">paralysis</span>. Consider these risks when scheduling patients for spinal procedures. Factors that can increase the risk of developing epidural or spinal <span class="product-label-link" type="condition" conceptid="4147001" conceptname="Hematoma">hematomas</span> in these patients include:</span></p>
<ul class="Disc">
<li><span class="Bold">Use of indwelling epidural catheters</span></li>
<li><span class="Bold">Concomitant use of other drugs that affect hemostasis, such as non-steroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, other anticoagulants.</span></li>
<li><span class="Bold">A history of traumatic or repeated epidural or spinal punctures</span></li>
<li><span class="Bold">A history of <span class="product-label-link" type="condition" conceptid="73302" conceptname="Curvature of spine">spinal deformity</span> or spinal surgery</span></li>
<li style="margin-left:-2em; padding-left:2em; border-left:1px solid; position:relative; zoom: 1;"><span class="XmChange"><span class="Bold">Optimal timing between the administration of Lovenox and neuraxial procedures is not known.</span></span></li>
</ul>
<p style="margin-left:-2em; padding-left:2em; border-left:1px solid; position:relative; zoom: 1;"><span class="XmChange"><span class="Bold">Monitor patients frequently for signs and symptoms of neurological impairment. If neurological compromise is noted, urgent treatment is necessary.</span></span></p>
<p><span class="Bold">Consider the benefits and risks before neuraxial intervention in patients anticoagulated or to be anticoagulated for thromboprophylaxis [see <span class="Italics"><a href="#S5.1">Warnings and Precautions (5.1)</a></span> and <span class="Italics"><a href="#S7">Drug Interactions (7)</a></span>].</span></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="S1"></a><a name="section-1"></a><p></p>
<h1>1	INDICATIONS AND USAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S1.1"></a><a name="section-1.1"></a><p></p>
<h2>1.1 Prophylaxis of <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">Deep Vein Thrombosis</span></h2>
<p class="First">Lovenox<span class="Sup">®</span> is indicated for the prophylaxis of <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">deep vein thrombosis</span> (DVT), which may lead to <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span> (PE):</p>
<ul>
<li>in patients undergoing abdominal surgery who are at risk for thromboembolic complications [see <span class="Italics"><a href="#S14.1">Clinical Studies (14.1)</a></span>].</li>
<li>in patients undergoing hip replacement surgery, during and following hospitalization.</li>
<li>in patients undergoing knee replacement surgery.</li>
<li>in medical patients who are at risk for thromboembolic complications due to severely restricted mobility during acute illness.</li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S1.2"></a><a name="section-1.2"></a><p></p>
<h2>1.2 Treatment of Acute <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">Deep Vein Thrombosis</span> </h2>
<p class="First">Lovenox is indicated for:</p>
<ul>
<li>the<span class="Bold"> inpatient treatment</span> of acute <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">deep vein thrombosis</span> <span class="Bold">with or without <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span>,</span> when administered in conjunction with warfarin sodium.</li>
<li>the <span class="Bold">outpatient treatment </span>of acute <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">deep vein thrombosis</span> <span class="Bold">without <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span></span> when administered in conjunction with warfarin sodium.</li>
</ul>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S1.3"></a><a name="section-1.3"></a><p></p>
<h2>1.3 Prophylaxis of Ischemic Complications of <span class="product-label-link" type="condition" conceptid="315296" conceptname="Preinfarction syndrome">Unstable Angina</span> and Non-Q-Wave <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Myocardial Infarction</span></h2>
<p class="First">Lovenox is indicated for the prophylaxis of ischemic complications of <span class="product-label-link" type="condition" conceptid="315296" conceptname="Preinfarction syndrome">unstable angina</span> and non-Q-wave <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, when concurrently administered with aspirin.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S1.4"></a><a name="section-1.4"></a><p></p>
<h2>1.4 Treatment of Acute ST-Segment Elevation <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Myocardial Infarction</span></h2>
<p class="First">Lovenox, when administered concurrently with aspirin, has been shown to reduce the rate of the combined endpoint of recurrent <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> in patients with acute ST-segment elevation <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> (<span class="product-label-link" type="condition" conceptid="312327" conceptname="Acute myocardial infarction">STEMI</span>) receiving <span class="product-label-link" type="condition" conceptid="4196955" conceptname="Thrombolysis">thrombolysis</span> and being managed medically or with percutaneous coronary intervention (PCI).</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="S2"></a><a name="section-2"></a><p></p>
<h1>2	DOSAGE AND ADMINISTRATION</h1>
<p class="First">All patients should be evaluated for a <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> disorder before administration of Lovenox, unless the medication is needed urgently. Since coagulation parameters are unsuitable for monitoring Lovenox activity, routine monitoring of coagulation parameters is not required [see<span class="Italics"><a href="#S5.9"> Warnings and Precautions (5.9)</a></span>].</p>
<p>For subcutaneous use, Lovenox should not be mixed with other injections or infusions. For intravenous use (<span class="Italics">i.e.,</span> for treatment of acute <span class="product-label-link" type="condition" conceptid="312327" conceptname="Acute myocardial infarction">STEMI</span>), Lovenox can be mixed with normal saline solution (0.9%) or 5% dextrose in water.</p>
<p>Lovenox is not intended for intramuscular administration.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.1"></a><a name="section-2.1"></a><p></p>
<h2>2.1 Adult Dosage</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.1.1"></a><p></p>
<p class="First"><span class="Italics"><span class="Underline">Abdominal Surgery:</span></span> In patients undergoing abdominal surgery who are at risk for thromboembolic complications, the recommended dose of Lovenox is <span class="Bold">40 mg once a day</span> administered by SC injection with the initial dose given 2 hours prior to surgery. The usual duration of administration is 7 to 10 days; up to 12 days administration has been administered in clinical trials.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.1.2"></a><p></p>
<p class="First"><span class="Italics"><span class="Underline">Hip or Knee Replacement Surgery:</span></span> In patients undergoing hip or knee replacement surgery, the recommended dose of Lovenox is <span class="Bold">30 mg every 12 hours</span> administered by SC injection. Provided that hemostasis has been established, the initial dose should be given 12 to 24 hours after surgery. For hip replacement surgery, a dose of <span class="Bold">40 mg once a day</span> SC, given initially 12 (±3) hours prior to surgery, may be considered. Following the initial phase of thromboprophylaxis in hip replacement surgery patients, it is recommended that continued prophylaxis with Lovenox 40 mg once a day be administered by SC injection for 3 weeks. The usual duration of administration is 7 to 10 days; up to 14 days administration has been administered in clinical trials.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.1.3"></a><p></p>
<p class="First"><span class="Italics"><span class="Underline">Medical Patients During Acute Illness:</span></span> In medical patients at risk for thromboembolic complications due to severely restricted mobility during acute illness, the recommended dose of Lovenox is <span class="Bold">40 mg once a day</span> administered by SC injection. The usual duration of administration is 6 to 11 days; up to 14 days of Lovenox has been administered in the controlled clinical trial.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.1.4"></a><p></p>
<p class="First"><span class="Italics"><span class="Underline">Treatment of <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">Deep Vein Thrombosis</span> with or without <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">Pulmonary Embolism</span>:</span></span> In<span class="Bold"> outpatient treatment</span>, patients with acute <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">deep vein thrombosis</span> without <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span> who can be treated at home, the recommended dose of Lovenox is <span class="Bold">1 mg/kg every 12 hours</span> administered SC. In <span class="Bold">inpatient (hospital) treatment</span>, patients with acute <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">deep vein thrombosis</span> with <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span> or patients with acute <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">deep vein thrombosis</span> without <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span> (who are not candidates for outpatient treatment), the recommended dose of Lovenox is <span class="Bold">1 mg/kg every 12 hours</span> administered SC <span class="Bold">or 1.5 mg/kg once a day</span> administered SC at the same time every day. In both outpatient and inpatient (hospital) treatments, warfarin sodium therapy should be initiated when appropriate (usually within 72 hours of Lovenox). Lovenox should be continued for a minimum of 5 days and until a therapeutic oral anticoagulant effect has been achieved (International Normalization Ratio 2.0 to 3.0). The average duration of administration is 7 days; up to 17 days of Lovenox administration has been administered in controlled clinical trials.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.1.5"></a><p></p>
<p class="First"><span class="Italics"><span class="Underline"><span class="product-label-link" type="condition" conceptid="315296" conceptname="Preinfarction syndrome">Unstable Angina</span> and Non-Q-Wave <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Myocardial Infarction</span>:</span></span> In patients with <span class="product-label-link" type="condition" conceptid="315296" conceptname="Preinfarction syndrome">unstable angina</span> or non-Q-wave <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, the recommended dose of Lovenox is <span class="Bold">1 mg/kg </span>administered SC <span class="Bold">every 12 hours </span>in conjunction with oral aspirin therapy (100 to 325 mg once daily). Treatment with Lovenox should be prescribed for a minimum of 2 days and continued until clinical stabilization. The usual duration of treatment is 2 to 8 days; up to 12.5 days of Lovenox has been administered in clinical trials [see<span class="Italics"><a href="#S5.2"> Warnings and Precautions (5.2)</a></span> and<span class="Italics"><a href="#S14.5"> Clinical Studies (14.5)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.1.6"></a><p></p>
<p class="First"><span class="Italics"><span class="Underline">Treatment of Acute ST-Segment Elevation <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Myocardial Infarction</span>:</span></span> In patients with acute ST-segment elevation <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, the recommended dose of Lovenox is a <span class="Bold">single IV bolus of 30 mg</span> plus a 1 mg/kg SC dose followed by 1 mg/kg administered SC every 12 hours (maximum 100 mg for the first two doses only, followed by 1 mg/kg dosing for the remaining doses). Dosage adjustments are recommended in patients ≥75 years of age [see <span class="Italics"><a href="#S2.3">Dosage and Administration (2.3)</a></span>]<span class="Italics">. </span>All patients should receive aspirin as soon as they are identified as having <span class="product-label-link" type="condition" conceptid="312327" conceptname="Acute myocardial infarction">STEMI</span> and maintained with 75 to 325 mg once daily unless contraindicated.</p>
<p>When administered in conjunction with a thrombolytic (fibrin-specific or non-fibrin specific), Lovenox should be given between 15 minutes before and 30 minutes after the start of fibrinolytic therapy. In the pivotal clinical study, the Lovenox treatment duration was 8 days or until hospital discharge, whichever came first. An optimal duration of treatment is not known, but it is likely to be longer than 8 days.</p>
<p>For patients managed with percutaneous coronary intervention (PCI): If the last Lovenox SC administration was given less than 8 hours before balloon inflation, no additional dosing is needed. If the last Lovenox SC administration was given more than 8 hours before balloon inflation, an IV bolus of 0.3 mg/kg of Lovenox should be administered [see <span class="Italics"><a href="#S5.2">Warnings and Precautions (5.2)</a></span>]<span class="Italics">.</span></p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.2"></a><a name="section-2.2"></a><p></p>
<h2>2.2 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">Although no dose adjustment is recommended in patients with moderate (creatinine clearance 30–50 mL/min) and mild (creatinine clearance 50–80 mL/min) <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, all such patients should be observed carefully for signs and symptoms of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>.</p>
<p>The recommended prophylaxis and treatment dosage regimens for patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (creatinine clearance &lt;30 mL/min) are described in Table 1 [see<span class="Italics"><a href="#S8.7"> Use in Specific Populations (8.7)</a></span> and<span class="Italics"><a href="#S12.3"> Clinical Pharmacology (12.3)</a></span>].</p>
<table width="80%">
<caption><span>Table 1 Dosage Regimens for Patients with Severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>  (creatinine clearance &lt;30mL/minute)</span></caption>
<col align="left" valign="top" width="60%">
<col align="left" valign="top" width="40%">
<thead><tr class="First Last">
<th class="Rrule" align="center">Indication</th>
<th align="center">Dosage Regimen</th>
</tr></thead>
<tbody>
<tr class="Botrule First">
<td class="Rrule" align="left">Prophylaxis in abdominal surgery</td>
<td align="left">30 mg administered SC once daily</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left">Prophylaxis in hip or knee replacement surgery</td>
<td align="left">30 mg administered SC once daily</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left">Prophylaxis in medical patients during acute illness</td>
<td align="left">30 mg administered SC once daily</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left">Inpatient treatment of acute <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">deep vein thrombosis</span> with or without <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span>, when administered in conjunction with warfarin sodium</td>
<td align="left">1 mg/kg administered SC once daily</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left">Outpatient treatment of acute <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">deep vein thrombosis</span> without <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span>, when administered in conjunction with warfarin sodium</td>
<td align="left">1 mg/kg administered SC once daily</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left">Prophylaxis of ischemic complications of <span class="product-label-link" type="condition" conceptid="315296" conceptname="Preinfarction syndrome">unstable angina</span> and non-Q-wave <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, when concurrently administered with aspirin</td>
<td align="left">1 mg/kg administered SC once daily</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left">Treatment of acute ST-segment elevation <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> in patients &lt;75 years of age, when administered in conjunction with aspirin</td>
<td align="left">30 mg single IV bolus plus a 1 mg/kg SC dose followed by 1 mg/kg administered SC once daily. </td>
</tr>
<tr class="Last">
<td class="Rrule" align="left">Treatment of acute ST-segment elevation <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> in geriatric patients ≥75 years of age, when administered in conjunction with aspirin</td>
<td align="left">1 mg/kg administered SC once daily (<span class="Bold">no </span>initial bolus)</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.3"></a><a name="section-2.3"></a><p></p>
<h2>2.3 Geriatric Patients  with Acute ST-Segment Elevation <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Myocardial Infarction</span></h2>
<p class="First">For treatment of acute ST-segment elevation <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> in geriatric patients ≥75 years of age, <span class="Bold">do not use an initial IV bolus</span>. Initiate dosing with <span class="Bold">0.75 mg/kg SC every 12 hours (maximum 75 mg for the first two doses only, followed by 0.75 mg/kg dosing for the remaining doses) </span>[see<span class="Italics"><a href="#S8.5"> Use in Specific Populations (8.5)</a></span> and<span class="Italics"><a href="#S12.3"> Clinical Pharmacology (12.3)</a></span>].</p>
<p>No dose adjustment is necessary for other indications in geriatric patients unless kidney function is impaired [see<span class="Italics"><a href="#S2.2"> Dosage and Administration (2.2)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.4"></a><a name="section-2.4"></a><p></p>
<h2>2.4 Administration</h2>
<p class="First">Lovenox is a clear, colorless to <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> yellow sterile solution, and as with other parenteral drug products, should be inspected visually for particulate matter and discoloration prior to administration.</p>
<p>The use of a tuberculin syringe or equivalent is recommended when using Lovenox multiple-dose vials to assure withdrawal of the appropriate volume of drug.</p>
<p>Lovenox must not be administered by intramuscular injection. Lovenox is intended for use under the guidance of a physician.</p>
<p>For subcutaneous administration, patients may self-inject only if their physicians determine that it is appropriate and with medical follow-up, as necessary. Proper training in subcutaneous injection technique (with or without the assistance of an injection device) should be provided.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.4.1"></a><p></p>
<p class="First"><span class="Italics"><span class="Underline">Subcutaneous Injection Technique:</span></span> Patients should be lying down and Lovenox administered by deep SC injection. To avoid the loss of drug when using the 30 and 40 mg prefilled syringes, do not expel the air bubble from the syringe before the injection. Administration should be alternated between the left and right anterolateral and left and right posterolateral abdominal wall. The whole length of the needle should be introduced into a skin fold held between the thumb and forefinger; the skin fold should be held throughout the injection. To minimize <span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">bruising</span>, do not rub the injection site after completion of the injection.</p>
<p>Lovenox prefilled syringes and graduated prefilled syringes are for single, one-time use only and are available with a system that shields the needle after injection.</p>
<p>Remove the prefilled syringe from the <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> packaging by <span class="product-label-link" type="condition" conceptid="4032013" conceptname="Desquamation">peeling</span> at the arrow as directed on the <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span>. Do not remove by pulling on the plunger as this may damage the syringe.</p>
<ol class="Arabic">
<li>Remove the needle shield by pulling it straight off the syringe (see<a href="#figa"> Figure A</a>). If adjusting the dose is required, the dose adjustment must be done prior to injecting the prescribed dose to the patient.<br><p class="First"><a name="figa"></a>Figure A<br><img alt="Figure A" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=53fd1302-9e1b-4e04-b06d-1a706547c388&amp;name=lovenoxnovaplus-01.jpg"></p>
</li>
<li>Inject using standard technique, pushing the plunger to the bottom of the syringe (see<a href="#figb"> Figure B</a>).<br><p class="First"><a name="figb"></a>Figure B<br><img alt="Figure B" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=53fd1302-9e1b-4e04-b06d-1a706547c388&amp;name=lovenoxnovaplus-02.jpg"></p>
</li>
<li>Remove the syringe from the injection site keeping your finger on the plunger rod (see<a href="#figc"> Figure C</a>).<br><p class="First"><a name="figc"></a>Figure C<br><img alt="Figure C" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=53fd1302-9e1b-4e04-b06d-1a706547c388&amp;name=lovenoxnovaplus-03.jpg"></p>
</li>
<li>Orient the needle away from you and others, and activate the safety system by firmly pushing the plunger rod. The protective sleeve will automatically cover the needle and an audible "click" will be heard to confirm shield activation (see<a href="#figd"> Figure D</a>).<br><p class="First"><a name="figd"></a>Figure D<br><img alt="Figure D" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=53fd1302-9e1b-4e04-b06d-1a706547c388&amp;name=lovenoxnovaplus-04.jpg"></p>
</li>
<li>Immediately dispose of the syringe in the nearest sharps container (see<a href="#fige"> Figure E</a>).<br><p class="First"><a name="fige"></a>Figure E<br><img alt="Figure E" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=53fd1302-9e1b-4e04-b06d-1a706547c388&amp;name=lovenoxnovaplus-05.jpg"></p>
</li>
</ol>
<p>NOTE:</p>
<ul>
<li>The safety system can only be activated once the syringe has been emptied.</li>
<li>Activation of the safety system must be done only after removing the needle from the patient's skin.</li>
<li>Do not replace the needle shield after injection.</li>
<li>The safety system should not be sterilized.</li>
</ul>
<p>Activation of the safety system may cause minimal splatter of fluid. For optimal safety activate the system while orienting it downwards away from yourself and others.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.4.2"></a><p></p>
<p class="First"><span class="Italics"><span class="Underline">Intravenous (Bolus) Injection Technique:</span></span> For intravenous injection, the multiple-dose vial should be used. Lovenox should be administered through an intravenous line. Lovenox should not be mixed or co-administered with other medications. To avoid the possible mixture of Lovenox with other drugs, the intravenous access chosen should be <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushed</span> with a sufficient amount of saline or dextrose solution prior to and following the intravenous bolus administration of Lovenox to clear the port of drug. Lovenox may be safely administered with normal saline solution (0.9%) or 5% dextrose in water.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="S3"></a><a name="section-3"></a><p></p>
<h1>3	DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">Lovenox is available in two concentrations:</p>
<div class="Section" data-sectionCode="42229-5">
<a name="S3.1"></a><a name="section-3.1"></a><p></p>
<h2>3.1 100 mg/mL Concentration</h2>
<table width="75%">
<col align="left" valign="top" width="35%">
<col align="left" valign="top" width="65%">
<tbody class="Headless">
<tr class="First Toprule">
<td align="left"><span class="Italics">-Prefilled Syringes</span></td>
<td align="left">30 mg/0.3 mL, 40 mg/0.4 mL</td>
</tr>
<tr>
<td align="left"><span class="Italics">-Graduated Prefilled Syringes</span></td>
<td align="left">60 mg/0.6 mL, 80 mg/0.8 mL, 100 mg/1 mL</td>
</tr>
<tr class="Botrule Last">
<td align="left"><span class="Italics">-Multiple-Dose Vials</span></td>
<td align="left">300 mg/3 mL</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S3.2"></a><a name="section-3.2"></a><p></p>
<h2>3.2 150  mg/mL Concentration</h2>
<table width="75%">
<col align="left" valign="top" width="35%">
<col align="left" valign="top" width="65%">
<tbody class="Headless"><tr class="First Last Toprule">
<td align="left">-<span class="Italics">Graduated Prefilled Syringes</span>
</td>
<td align="left">120 mg/0.8 mL, 150 mg/1 mL</td>
</tr></tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="S4"></a><a name="section-4"></a><p></p>
<h1>4	CONTRAINDICATIONS</h1>
<ul>
<li>Active major <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span></li>
<li><span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span> associated with a positive <span class="Italics">in vitro</span> test for anti-platelet antibody in the presence of enoxaparin sodium</li>
<li>Known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to enoxaparin sodium (<span class="Italics">e.g.,</span> <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, anaphylactic/<span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span>) [see<span class="Italics"><a href="#S6.2"> Adverse Reactions (6.2)</a></span>]</li>
<li>Known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to heparin or pork products </li>
<li>Known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to benzyl alcohol (which is in only the multi-dose formulation of Lovenox) [see <span class="Italics"><a href="#S5.8">Warnings and Precautions (5.8)</a></span>]</li>
</ul>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="S5"></a><a name="section-5"></a><p></p>
<h1>5	WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.1"></a><a name="section-5.1"></a><p></p>
<h2>5.1 Increased Risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Hemorrhage</span></h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">Cases of epidural or spinal <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span> and subsequent <span class="product-label-link" type="condition" conceptid="4147001" conceptname="Hematoma">hematomas</span> have been reported with the use of Lovenox and epidural or spinal anesthesia/<span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> or spinal puncture procedures, resulting in long-term or permanent <span class="product-label-link" type="condition" conceptid="440377" conceptname="Paralysis">paralysis</span>.  The risk of these events is higher with the use of post-operative indwelling epidural catheters, with the concomitant use of additional drugs affecting hemostasis such as NSAIDs, with traumatic or repeated epidural or spinal puncture, or in patients with a history of spinal surgery or <span class="product-label-link" type="condition" conceptid="73302" conceptname="Curvature of spine">spinal deformity</span> [see<span class="Italics"><a href="#BOX"> Boxed Warning</a>,<a href="#S6.2"> Adverse Reactions (6.2) </a></span>and<span class="Italics"><a href="#S7"> Drug Interactions (7)</a></span>].</span></p>
<p style="border-left:1px solid;"><span class="XmChange">To reduce the potential risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> associated with the concurrent use of enoxaparin sodium and epidural or spinal anesthesia/<span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> or spinal puncture, consider the pharmacokinetic profile of enoxaparin [see<span class="Italics"><a href="#S12.3"> Clinical Pharmacology (12.3)</a></span>]. Placement or removal of an epidural catheter or lumbar puncture is best performed when the anticoagulant effect of enoxaparin is low; however, the exact timing to reach a sufficiently low anticoagulant effect in each patient is not known.</span></p>
<p style="border-left:1px solid;"><span class="XmChange">Placement or removal of a catheter should be delayed for at least 12 hours after administration of lower doses (30 mg once or twice daily or 40 mg once daily) of Lovenox, and at least 24 hours after the administration of higher doses (0.75 mg/kg twice daily, 1 mg/kg twice daily, or 1.5 mg/kg once daily) of Lovenox. Anti-Xa levels are still detectable at these time points, and these delays are not a guarantee that neuraxial <span class="product-label-link" type="condition" conceptid="4147001" conceptname="Hematoma">hematoma</span> will be avoided. Patients receiving the 0.75 mg/kg twice daily dose or the1 mg/kg twice daily dose should not receive the second enoxaparin dose in the twice daily regimen to allow a longer delay before catheter placement or removal.   Likewise, although a specific recommendation for timing of a subsequent Lovenox dose after catheter removal cannot be made, consider delaying this next dose for at least four hours, based on a benefit-risk assessment considering both the risk for <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span> and the risk for <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> in the context of the procedure and patient risk factors. For patients with creatinine clearance &lt;30mL/minute, additional considerations are necessary because elimination of enoxaparin is more prolonged; consider doubling the timing of removal of a catheter, at least 24 hours for the lower prescribed dose of Lovenox (30 mg once daily) and at least 48 hours for the higher dose (1 mg/kg/day) [see<span class="Italics"><a href="#S12.3"> Clinical Pharmacology (12.3)</a></span>].</span></p>
<p style="border-left:1px solid;"><span class="XmChange">Should the physician decide to administer anticoagulation in the context of epidural or spinal anesthesia/<span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> or lumbar puncture, frequent monitoring must be exercised to detect any signs and symptoms of neurological impairment such as midline <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">back pain</span>, sensory and motor deficits (<span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span> or <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> in lower limbs), bowel and/or bladder dysfunction. Instruct patients to report immediately if they experience any of the above signs or symptoms. If signs or symptoms of spinal <span class="product-label-link" type="condition" conceptid="4147001" conceptname="Hematoma">hematoma</span> are suspected, initiate urgent diagnosis and treatment including consideration for spinal cord decompression even though such treatment may not prevent or reverse neurological sequelae.  </span></p>
<p>Lovenox should be used with extreme caution in conditions with increased risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>, such as <span class="product-label-link" type="condition" conceptid="4116649" conceptname="Bacterial endocarditis">bacterial endocarditis</span>, congenital or acquired <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> disorders, active ulcerative and angiodysplastic gastrointestinal disease, <span class="product-label-link" type="condition" conceptid="4046362" conceptname="Hemorrhagic cerebral infarction">hemorrhagic stroke</span>, or shortly after brain, spinal, or ophthalmological surgery, or in patients treated concomitantly with platelet inhibitors.</p>
<p>Major <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhages</span> including retroperitoneal and intracranial <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> have been reported. Some of these cases have been fatal.</p>
<p><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> can occur at any site during therapy with Lovenox. An unexplained <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">fall</span> in hematocrit or blood pressure should lead to a search for a <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> site.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.2"></a><a name="section-5.2"></a><p></p>
<h2>5.2 Percutaneous Coronary Revascularization Procedures</h2>
<p class="First">To minimize the risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> following the vascular instrumentation during the treatment of <span class="product-label-link" type="condition" conceptid="315296" conceptname="Preinfarction syndrome">unstable angina</span>, non-Q-wave <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> and acute ST-segment elevation <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, adhere precisely to the intervals recommended between Lovenox doses. It is important to achieve hemostasis at the puncture site after PCI. In case a closure device is used, the sheath can be removed immediately. If a manual compression method is used, sheath should be removed 6 hours after the last IV/SC Lovenox. If the treatment with enoxaparin sodium is to be continued, the next scheduled dose should be given no sooner than 6 to 8 hours after sheath removal. The site of the procedure should be observed for signs of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> or <span class="product-label-link" type="condition" conceptid="4147001" conceptname="Hematoma">hematoma</span> formation [see <span class="Italics"><a href="#S2.1">Dosage and Administration (2.1)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.3"></a><a name="section-5.3"></a><p></p>
<h2>5.3 Use of Lovenox with Concomitant Medical Conditions</h2>
<p class="First">Lovenox should be used with care in patients with a <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> diathesis, uncontrolled arterial <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> or a history of recent gastrointestinal ulceration, <span class="product-label-link" type="condition" conceptid="4174977" conceptname="Diabetic retinopathy">diabetic retinopathy</span>, renal dysfunction and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.4"></a><a name="section-5.4"></a><p></p>
<h2>5.4 History of <span class="product-label-link" type="condition" conceptid="433749" conceptname="Heparin-induced thrombocytopenia">Heparin-Induced Thrombocytopenia</span></h2>
<p class="First">Lovenox should be used with extreme caution in patients with a history of <span class="product-label-link" type="condition" conceptid="433749" conceptname="Heparin-induced thrombocytopenia">heparin-induced thrombocytopenia</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.5"></a><a name="section-5.5"></a><p></p>
<h2>5.5 <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span> can occur with the administration of Lovenox.</p>
<p>Moderate <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> (platelet counts between 100,000/mm<span class="Sup">3</span> and 50,000/mm<span class="Sup">3</span>) occurred at a rate of 1.3% in patients given Lovenox, 1.2% in patients given heparin, and 0.7% in patients given placebo in clinical trials.</p>
<p>Platelet counts less than 50,000/mm<span class="Sup">3</span> occurred at a rate of 0.1% in patients given Lovenox, in 0.2% of patients given heparin, and 0.4% of patients given placebo in the same trials.</p>
<p><span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span> of any degree should be monitored closely. If the platelet count <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">falls</span> below 100,000/mm<span class="Sup">3</span>, Lovenox should be discontinued. Cases of <span class="product-label-link" type="condition" conceptid="433749" conceptname="Heparin-induced thrombocytopenia">heparin-induced thrombocytopenia</span> with <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span> have also been observed in clinical practice. Some of these cases were complicated by organ <span class="product-label-link" type="condition" conceptid="4206471" conceptname="Infarct">infarction</span>, limb <span class="product-label-link" type="condition" conceptid="4200991" conceptname="Ischemia">ischemia</span>, or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> [<span class="Italics">see<a href="#S5.4"> Warnings and Precautions (5.4)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.6"></a><a name="section-5.6"></a><p></p>
<h2>5.6 Interchangeability with Other Heparins</h2>
<p class="First">Lovenox cannot be used interchangeably (unit for unit) with heparin or other low molecular weight heparins as they differ in manufacturing process, molecular weight distribution, anti-Xa and anti-IIa activities, units, and dosage. Each of these medicines has its own instructions for use.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.7"></a><a name="section-5.7"></a><p></p>
<h2>5.7 Pregnant Women with Mechanical Prosthetic Heart Valves</h2>
<p class="First">The use of Lovenox for thromboprophylaxis in pregnant women with mechanical prosthetic heart valves has not been adequately studied. In a clinical study of pregnant women with mechanical prosthetic heart valves given enoxaparin (1 mg/kg twice daily) to reduce the risk of <span class="product-label-link" type="condition" conceptid="4159647" conceptname="Thromboembolic disorder">thromboembolism</span>, 2 of 8 women developed clots resulting in blockage of the valve and leading to maternal and <span class="product-label-link" type="condition" conceptid="4079844" conceptname="Fetal death">fetal death</span>. Although a causal relationship has not been established these <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> may have been due to therapeutic failure or inadequate anticoagulation. No patients in the heparin/warfarin group (0 of 4 women) died. There also have been isolated postmarketing reports of valve <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span> in pregnant women with mechanical prosthetic heart valves while receiving enoxaparin for thromboprophylaxis. Women with mechanical prosthetic heart valves may be at higher risk for <span class="product-label-link" type="condition" conceptid="4159647" conceptname="Thromboembolic disorder">thromboembolism</span> during pregnancy, and, when pregnant, have a higher rate of fetal loss from <span class="product-label-link" type="condition" conceptid="443213" conceptname="Stillbirth">stillbirth</span>, <span class="product-label-link" type="condition" conceptid="4067106" conceptname="Miscarriage">spontaneous abortion</span> and <span class="product-label-link" type="condition" conceptid="4086393" conceptname="Premature delivery">premature delivery</span>. Therefore, frequent monitoring of peak and trough anti-Factor Xa levels, and adjusting of dosage may be needed [see<span class="Italics"><a href="#S8.6"> Use in Specific Populations (8.6)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.8"></a><a name="section-5.8"></a><p></p>
<h2>5.8 Benzyl Alcohol</h2>
<p class="First">Lovenox multiple-dose vials contain benzyl alcohol as a preservative. The administration of medications containing benzyl alcohol as a preservative to premature neonates has been associated with a fatal "<span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">gasping</span> syndrome". Because benzyl alcohol may cross the placenta, Lovenox multiple-dose vials, preserved with benzyl alcohol, should be used with caution in pregnant women and only if clearly needed [see<span class="Italics"><a href="#S8.1"> Use in Specific Populations (8.1)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="S5.9"></a><a name="section-5.9"></a><p></p>
<h2>5.9 Laboratory Tests</h2>
<p class="First">Periodic complete blood counts, including platelet count, and stool occult blood tests are recommended during the course of treatment with Lovenox. When administered at recommended prophylaxis doses, routine coagulation tests such as <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">Prothrombin</span> Time (PT) and <span class="product-label-link" type="condition" conceptid="44809202" conceptname="Activated partial thromboplastin time">Activated Partial Thromboplastin Time</span> (aPTT) are relatively insensitive measures of Lovenox activity and, therefore, unsuitable for monitoring. Anti-Factor Xa may be used to monitor the anticoagulant effect of Lovenox in patients with significant <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. If during Lovenox therapy abnormal coagulation parameters or <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> should occur, anti-Factor Xa levels may be used to monitor the anticoagulant effects of Lovenox [see<span class="Italics"><a href="#S12.3"> Clinical Pharmacology (12.3)</a></span>].</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="S6"></a><a name="section-6"></a><p></p>
<h1>6	ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.1"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trials Experience</h2>
<p class="First">The following serious adverse reactions are also discussed in other sections of the labeling:</p>
<ul>
<li> Spinal/<span class="product-label-link" type="condition" conceptid="4176148" conceptname="Extradural intracranial hematoma">epidural hematoma</span> [see <span class="Italics"><a href="#BOX">Boxed Warning</a></span> and<span class="Italics"><a href="#S5.1"> Warnings and Precautions (5.1)</a></span>]</li>
<li> Increased Risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Hemorrhage</span> [see <span class="Italics"><a href="#S5.1">Warnings and Precautions (5.1)</a></span>]</li>
<li> <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span> [see <span class="Italics"><a href="#S5.5">Warnings and Precautions (5.5)</a></span>]</li>
</ul>
<p>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.</p>
<p>During clinical development for the approved indications, 15,918 patients were exposed to enoxaparin sodium. These included 1,228 for prophylaxis of <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">deep vein thrombosis</span> following abdominal surgery in patients at risk for thromboembolic complications, 1,368 for prophylaxis of <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">deep vein thrombosis</span> following hip or knee replacement surgery, 711 for prophylaxis of <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">deep vein thrombosis</span> in medical patients with severely restricted mobility during acute illness, 1,578 for prophylaxis of ischemic complications in <span class="product-label-link" type="condition" conceptid="315296" conceptname="Preinfarction syndrome">unstable angina</span> and non-Q-wave <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, 10,176 for treatment of acute ST-elevation <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, and 857 for treatment of <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">deep vein thrombosis</span> with or without <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span>. Enoxaparin sodium doses in the clinical trials for prophylaxis of <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">deep vein thrombosis</span> following abdominal or hip or knee replacement surgery or in medical patients with severely restricted mobility during acute illness ranged from 40 mg SC once daily to 30 mg SC twice daily. In the clinical studies for prophylaxis of ischemic complications of <span class="product-label-link" type="condition" conceptid="315296" conceptname="Preinfarction syndrome">unstable angina</span> and non-Q-wave <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> doses were 1 mg/kg every 12 hours and in the clinical studies for treatment of acute ST-segment elevation <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> enoxaparin sodium doses were a 30 mg IV bolus followed by 1 mg/kg every 12 hours SC.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.1"></a><p></p>
<p class="First"><span class="Bold Italics"><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Hemorrhage</span></span></p>
<p>The incidence of major hemorrhagic complications during Lovenox treatment has been low.</p>
<p>The following rates of major <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> events have been reported during clinical trials with Lovenox [see Tables 2 to 7].</p>
<table width="75%">
<caption><span>Table 2 Major <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> Episodes Following Abdominal and Colorectal Surgery<a name="footnote-reference-2" href="#footnote-2" class="Sup">*</a></span></caption>
<col align="left" valign="top" width="33%">
<col align="center" valign="top" width="34%">
<col align="center" valign="top" width="33%">
<thead>
<tr class="Botrule First">
<th class="Rrule" align="left" rowspan="2" valign="bottom">Indications</th>
<th align="center" colspan="2">Dosing Regimen</th>
</tr>
<tr class="Last">
<th class="Rrule" align="center">
<span class="Underline">Lovenox</span><br>40 mg q.d. SC</th>
<th align="center">
<span class="Underline">Heparin</span><br>5000 U q8h SC</th>
</tr>
</thead>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-2" href="#footnote-reference-2">*</a></dt>
<dd><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> complications were considered major: (1) if the <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span> caused a significant clinical event, or (2) if accompanied by a hemoglobin decrease ≥ 2 g/dL or transfusion of 2 or more units of blood products. Retroperitoneal, intraocular, and <span class="product-label-link" type="condition" conceptid="439847" conceptname="Intracranial hemorrhage">intracranial hemorrhages</span> were always considered major.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Rrule" align="left"><span class="Bold">Abdominal Surgery</span></td>
<td class="Rrule" align="center">n = 555<br>23 (4%)</td>
<td align="center">n = 560<br>16 (3%)</td>
</tr>
<tr class="Last">
<td class="Rrule" align="left"><span class="Bold">Colorectal Surgery</span></td>
<td class="Rrule" align="center">n = 673<br>28 (4%)</td>
<td align="center">n = 674<br>21 (3%)</td>
</tr>
</tbody>
</table>
<table width="100%">
<caption><span>Table 3 Major <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> Episodes Following Hip or Knee Replacement Surgery<a name="footnote-reference-3" href="#footnote-3" class="Sup">*</a></span></caption>
<col align="left" valign="top" width="34%">
<col align="center" valign="top" width="22%">
<col align="center" valign="top" width="22%">
<col align="center" valign="top" width="22%">
<thead>
<tr class="Botrule First">
<th class="Rrule" align="left" rowspan="2" valign="bottom">Indications</th>
<th align="center" colspan="3">Dosing Regimen</th>
</tr>
<tr class="Last">
<th class="Rrule" align="center">
<span class="Underline">Lovenox</span><br>40 mg q.d. SC</th>
<th class="Rrule" align="center">
<span class="Underline">Lovenox</span><br>30 mg q12h SC</th>
<th align="center">
<span class="Underline">Heparin</span><br>15,000 U/24h SC</th>
</tr>
</thead>
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-3" href="#footnote-reference-3">*</a></dt>
<dd><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> complications were considered major: (1) if the <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span> caused a significant clinical event, or (2) if accompanied by a hemoglobin decrease ≥ 2 g/dL or transfusion of 2 or more units of blood products. Retroperitoneal and <span class="product-label-link" type="condition" conceptid="439847" conceptname="Intracranial hemorrhage">intracranial hemorrhages</span> were always considered major. In the knee replacement surgery trials, <span class="product-label-link" type="condition" conceptid="433778" conceptname="Orbital hemorrhage">intraocular hemorrhages</span> were also considered major <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhages</span>.</dd>
<dt><a name="footnote-4" href="#footnote-reference-4">†</a></dt>
<dd>Lovenox 30 mg every 12 hours SC initiated 12 to 24 hours after surgery and continued for up to 14 days after surgery</dd>
<dt><a name="footnote-5" href="#footnote-reference-5">‡</a></dt>
<dd>Lovenox 40 mg SC once a day initiated up to 12 hours prior to surgery and continued for up to 7 days after surgery</dd>
<dt><a name="footnote-6" href="#footnote-reference-6">§</a></dt>
<dd>Lovenox 40 mg SC once a day for up to 21 days after discharge</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Rrule" align="left">
<span class="Bold">Hip Replacement Surgery without Extended Prophylaxis</span><a name="footnote-reference-4" href="#footnote-4" class="Sup">†</a>
</td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center">n = 786<br>31 (4%)</td>
<td align="center">n = 541<br>32 (6%)</td>
</tr>
<tr>
<td class="Rrule" align="left"><span class="Bold">Hip Replacement Surgery with Extended Prophylaxis</span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td class="Rrule" align="right">Peri-operative Period<a name="footnote-reference-5" href="#footnote-5" class="Sup">‡</a>
</td>
<td class="Botrule Rrule" align="center">n = 288<br>4 (2%)</td>
<td class="Botrule Rrule" align="center"></td>
<td class="Botrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="right">Extended Prophylaxis Period<a name="footnote-reference-6" href="#footnote-6" class="Sup">§</a>
</td>
<td class="Rrule" align="center">n = 221<br>0 (0%)</td>
<td class="Rrule" align="center"></td>
<td align="center"></td>
</tr>
<tr class="Last">
<td class="Rrule" align="left">
<span class="Bold">Knee Replacement Surgery without Extended Prophylaxis</span><a href="#footnote-4" class="Sup">†</a>
</td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center">n = 294<br>3 (1%)</td>
<td align="center">n = 225<br>3 (1%)</td>
</tr>
</tbody>
</table>
<p>NOTE: At no time point were the 40 mg once a day pre-operative and the 30 mg every 12 hours post-operative hip replacement surgery <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> regimens compared in clinical trials.</p>
<p>Injection site <span class="product-label-link" type="condition" conceptid="4147001" conceptname="Hematoma">hematomas</span> during the extended prophylaxis period after hip replacement surgery occurred in 9% of the Lovenox patients versus 1.8% of the placebo patients.</p>
<table width="100%">
<caption><span>Table 4 Major <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> Episodes in Medical Patients with Severely Restricted Mobility During Acute Illness<a name="footnote-reference-7" href="#footnote-7" class="Sup">*</a></span></caption>
<col align="left" valign="top" width="34%">
<col align="center" valign="top" width="22%">
<col align="center" valign="top" width="22%">
<col align="center" valign="top" width="22%">
<thead>
<tr class="Botrule First">
<th class="Rrule" align="left" rowspan="2" valign="bottom">Indications</th>
<th align="center" colspan="3">Dosing Regimen</th>
</tr>
<tr class="Last">
<th class="Rrule" align="center">
<span class="Underline">Lovenox</span><a name="footnote-reference-8" href="#footnote-8" class="Sup">†</a><br>20 mg q.d. SC</th>
<th class="Rrule" align="center">
<span class="Underline">Lovenox</span><a href="#footnote-8" class="Sup">†</a><br>40 mg q.d. SC</th>
<th align="center"><span class="Underline">Placebo<a href="#footnote-8" class="Sup">†</a></span></th>
</tr>
</thead>
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-7" href="#footnote-reference-7">*</a></dt>
<dd><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> complications were considered major: (1) if the <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span> caused a significant clinical event, (2) if the <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span> caused a decrease in hemoglobin of ≥ 2 g/dL or transfusion of 2 or more units of blood products. Retroperitoneal and <span class="product-label-link" type="condition" conceptid="439847" conceptname="Intracranial hemorrhage">intracranial hemorrhages</span> were always considered major although none were reported during the trial.</dd>
<dt><a name="footnote-8" href="#footnote-reference-8">†</a></dt>
<dd>The rates represent major <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> on study medication up to 24 hours after last dose.</dd>
</dl></td></tr></tfoot>
<tbody><tr class="First Last">
<td class="Rrule" align="left"><span class="Bold">Medical Patients During Acute Illness</span></td>
<td class="Rrule" align="center">n = 351<br>1 (&lt;1%)</td>
<td class="Rrule" align="center">n = 360<br>3 (&lt;1%)</td>
<td align="center">n = 362<br>2 (&lt;1%)</td>
</tr></tbody>
</table>
<table width="100%">
<caption><span>Table 5 Major <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> Episodes in <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">Deep Vein Thrombosis</span> with or without <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">Pulmonary Embolism</span> Treatment <a name="footnote-reference-9" href="#footnote-9" class="Sup">*</a></span></caption>
<col align="left" valign="top" width="34%">
<col align="center" valign="top" width="22%">
<col align="center" valign="top" width="22%">
<col align="center" valign="top" width="22%">
<thead>
<tr class="Botrule First">
<th class="Rrule" align="left" rowspan="2" valign="bottom">Indication<br> </th>
<th align="center" colspan="3">Dosing Regimen<a name="footnote-reference-10" href="#footnote-10" class="Sup">†</a>
</th>
</tr>
<tr class="Last">
<th class="Rrule" align="center">
<span class="Underline">Lovenox</span><br>1.5 mg/kg q.d. SC</th>
<th class="Rrule" align="center">
<span class="Underline">Lovenox</span><br>1 mg/kg q12h SC</th>
<th align="center">
<span class="Underline">Heparin</span><br>aPTT Adjusted IV Therapy</th>
</tr>
</thead>
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-9" href="#footnote-reference-9">*</a></dt>
<dd><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> complications were considered major: (1) if the <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span> caused a significant clinical event, or (2) if accompanied by a hemoglobin decrease ≥ 2 g/dL or transfusion of 2 or more units of blood products. Retroperitoneal, intraocular, and <span class="product-label-link" type="condition" conceptid="439847" conceptname="Intracranial hemorrhage">intracranial hemorrhages</span> were always considered major.</dd>
<dt><a name="footnote-10" href="#footnote-reference-10">†</a></dt>
<dd>All patients also received warfarin sodium (dose-adjusted according to PT to achieve an INR of 2.0 to 3.0) commencing within 72 hours of Lovenox or standard heparin therapy and continuing for up to 90 days.</dd>
</dl></td></tr></tfoot>
<tbody><tr class="First Last">
<td class="Rrule" align="left"><span class="Bold">Treatment of DVT and PE</span></td>
<td class="Rrule" align="center">n = 298<br>5 (2%)</td>
<td class="Rrule" align="center">n = 559<br>9 (2%)</td>
<td align="center">n = 554<br>9 (2%)</td>
</tr></tbody>
</table>
<table width="75%">
<caption><span>Table 6 Major <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> Episodes in <span class="product-label-link" type="condition" conceptid="315296" conceptname="Preinfarction syndrome">Unstable Angina</span> and Non-Q-Wave <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Myocardial Infarction</span></span></caption>
<col align="left" valign="top" width="33%">
<col align="center" valign="top" width="33%">
<col align="center" valign="top" width="34%">
<thead>
<tr class="Botrule First">
<th class="Rrule" align="left" rowspan="2" valign="bottom">Indication</th>
<th align="center" colspan="2">Dosing Regimen</th>
</tr>
<tr class="Last">
<th class="Rrule" align="center">
<span class="Underline">Lovenox</span><a name="footnote-reference-11" href="#footnote-11" class="Sup">*</a><br>1 mg/kg q12h SC</th>
<th align="center">
<span class="Underline">Heparin</span><a href="#footnote-11" class="Sup">*</a><br>aPTT Adjusted IV Therapy </th>
</tr>
</thead>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-11" href="#footnote-reference-11">*</a></dt>
<dd>The rates represent major <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> on study medication up to 12 hours after dose.</dd>
<dt><a name="footnote-12" href="#footnote-reference-12">†</a></dt>
<dd>Aspirin therapy was administered concurrently (100 to 325 mg per day).</dd>
<dt><a name="footnote-13" href="#footnote-reference-13">‡</a></dt>
<dd><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> complications were considered major: (1) if the <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span> caused a significant clinical event, or (2) if accompanied by a hemoglobin decrease by ≥ 3 g/dL or transfusion of 2 or more units of blood products. Intraocular<span class="Italics">, </span>retroperitoneal, and <span class="product-label-link" type="condition" conceptid="439847" conceptname="Intracranial hemorrhage">intracranial hemorrhages</span> were always considered major.</dd>
</dl></td></tr></tfoot>
<tbody><tr class="First Last">
<td class="Rrule" align="left">
<span class="Bold"><span class="product-label-link" type="condition" conceptid="315296" conceptname="Preinfarction syndrome">Unstable Angina</span> and Non-Q-Wave MI</span><a name="footnote-reference-12" href="#footnote-12" class="Sup">†</a><span class="Sup">,</span><a name="footnote-reference-13" href="#footnote-13" class="Sup">‡</a>
</td>
<td class="Rrule" align="center">n = 1578<br>17 (1%)</td>
<td align="center">n = 1529<br>18 (1%)</td>
</tr></tbody>
</table>
<table width="75%">
<caption><span>Table 7 Major <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> Episodes in Acute ST-Segment Elevation <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Myocardial Infarction</span></span></caption>
<col align="left" valign="top" width="40%">
<col align="center" valign="top" width="30%">
<col align="center" valign="top" width="30%">
<thead>
<tr class="Botrule First">
<th class="Rrule" align="left" rowspan="2" valign="middle">Indication</th>
<th align="center" colspan="2">Dosing Regimen</th>
</tr>
<tr class="Last">
<th class="Rrule" align="center">
<span class="Underline">Lovenox</span><a name="footnote-reference-14" href="#footnote-14" class="Sup">*</a><br>Initial 30 mg IV bolus followed by 1 mg/kg q12h SC</th>
<th align="center">
<span class="Underline">Heparin</span><a href="#footnote-14" class="Sup">*</a><br>aPTT Adjusted IV Therapy </th>
</tr>
</thead>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-14" href="#footnote-reference-14">*</a></dt>
<dd>The rates represent major <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> (including ICH) up to 30 days </dd>
<dt><a name="footnote-15" href="#footnote-reference-15">†</a></dt>
<dd><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleedings</span> were considered major if the <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span> caused a significant clinical event associated with a hemoglobin decrease by ≥ 5 g/dL. ICH were always considered major. </dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Rrule" align="left"><span class="Bold">Acute ST-Segment Elevation  <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Myocardial Infarction</span></span></td>
<td class="Rrule" align="center">n = 10176<br>n (%)</td>
<td align="center">n = 10151<br>n (%)</td>
</tr>
<tr>
<td class="Rrule" align="left">- Major <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> (including ICH) <a name="footnote-reference-15" href="#footnote-15" class="Sup">†</a>
</td>
<td class="Rrule" align="center">211 (2.1)</td>
<td align="center">138 (1.4)</td>
</tr>
<tr class="Last">
<td class="Rrule" align="left">- <span class="product-label-link" type="condition" conceptid="439847" conceptname="Intracranial hemorrhage">Intracranial hemorrhages</span> (ICH)</td>
<td class="Rrule" align="center">84 (0.8)</td>
<td align="center">66 (0.7)</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.2"></a><p></p>
<p class="First"><span class="Bold Italics">Elevations of Serum Aminotransferases</span></p>
<p>Asymptomatic increases in aspartate (AST [<span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span>]) and alanine (ALT [SGPT]) aminotransferase levels greater than three times the upper limit of normal of the laboratory reference range have been reported in up to 6.1% and 5.9% of patients, respectively, during treatment with Lovenox. Similar significant increases in aminotransferase levels have also been observed in patients and healthy volunteers treated with heparin and other low molecular weight heparins. Such elevations are fully reversible and are rarely associated with increases in bilirubin.</p>
<p>Since aminotransferase determinations are important in the differential diagnosis of <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, liver disease, and pulmonary emboli, elevations that might be caused by drugs like Lovenox should be interpreted with caution.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.3"></a><p></p>
<p class="First"><span class="Bold Italics">Local Reactions</span></p>
<p>Mild local irritation, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="4147001" conceptname="Hematoma">hematoma</span>, <span class="product-label-link" type="condition" conceptid="4118793" conceptname="Ecchymosis">ecchymosis</span>, and <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span> may follow SC injection of Lovenox.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.3.1"></a><p></p>
<p class="First"><span class="Bold">Adverse Reactions in Patients Receiving Lovenox for Prophylaxis or Treatment of DVT, PE:</span></p>
<p>Other adverse reactions that were thought to be possibly or probably related to treatment with Lovenox, heparin, or placebo in clinical trials with patients undergoing hip or knee replacement surgery, abdominal or colorectal surgery, or treatment for DVT and that occurred at a rate of at least 2% in the Lovenox group, are provided below [see Tables 8 to 11].</p>
<table width="75%">
<caption><span>Table 8 Adverse Reactions Occurring at ≥2% Incidence in Lovenox-Treated Patients Undergoing Abdominal or Colorectal Surgery</span></caption>
<col align="left" valign="top" width="40%">
<col align="center" valign="top" width="15%">
<col align="center" valign="top" width="15%">
<col align="center" valign="top" width="15%">
<col align="center" valign="top" width="15%">
<thead>
<tr class="Botrule First">
<th class="Rrule" align="left" rowspan="3" valign="bottom">Adverse Reaction</th>
<th align="center" colspan="4">Dosing Regimen</th>
</tr>
<tr>
<th class="Rrule" align="center" colspan="2">
<span class="Underline">Lovenox</span><br>40 mg q.d. SC<br>n = 1228<br>%</th>
<th align="center" colspan="2">
<span class="Underline">Heparin</span><br>5000 U q8h SC<br>n = 1234<br>%</th>
</tr>
<tr class="Last">
<th align="center">Severe</th>
<th class="Rrule" align="center">Total</th>
<th align="center">Severe</th>
<th align="center">Total</th>
</tr>
</thead>
<tbody>
<tr class="Botrule First">
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Hemorrhage</span></td>
<td align="center">&lt;1</td>
<td class="Rrule" align="center">7</td>
<td align="center">&lt;1</td>
<td align="center">6</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span></td>
<td align="center">&lt;1</td>
<td class="Rrule" align="center">3</td>
<td align="center">&lt;1</td>
<td align="center">3</td>
</tr>
<tr class="Last">
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4118793" conceptname="Ecchymosis">Ecchymosis</span></td>
<td align="center">0</td>
<td class="Rrule" align="center">3</td>
<td align="center">0</td>
<td align="center">3</td>
</tr>
</tbody>
</table>
<table width="100%">
<caption><span>Table 9 Adverse Reactions Occurring at ≥2% Incidence in Lovenox-Treated Patients Undergoing Hip or Knee Replacement Surgery</span></caption>
<col align="left" valign="top" width="20%">
<col align="center" valign="top" width="8%">
<col align="center" valign="top" width="8%">
<col align="center" valign="top" width="8%">
<col align="center" valign="top" width="8%">
<col align="center" valign="top" width="8%">
<col align="center" valign="top" width="8%">
<col align="center" valign="top" width="8%">
<col align="center" valign="top" width="8%">
<col align="center" valign="top" width="8%">
<col align="center" valign="top" width="8%">
<thead>
<tr class="Botrule First">
<th class="Rrule" align="left" rowspan="5" valign="bottom">Adverse Reaction</th>
<th align="center" colspan="11">Dosing Regimen</th>
</tr>
<tr>
<th class="Rrule" align="center" colspan="4">
<span class="Underline">Lovenox</span><br>40 mg q.d. SC</th>
<th class="Rrule" align="center" colspan="2">
<span class="Underline">Lovenox</span><br>30 mg q12h SC</th>
<th class="Rrule" align="center" colspan="2">
<span class="Underline">Heparin</span><br>15,000 U/24h SC</th>
<th align="center" colspan="2">
<span class="Underline">Placebo</span><br>q12h SC</th>
</tr>
<tr>
<th class="Rrule" align="center" colspan="2">Peri-operative Period</th>
<th class="Rrule" align="center" colspan="2">Extended Prophylaxis Period</th>
<th class="Rrule" align="center" colspan="2"></th>
<th class="Rrule" align="center" colspan="2"></th>
<th align="center" colspan="2"></th>
</tr>
<tr>
<th class="Rrule" align="center" colspan="2">n = 288 <a name="footnote-reference-16" href="#footnote-16" class="Sup">*</a><br>%</th>
<th class="Rrule" align="center" colspan="2">n = 131 <a name="footnote-reference-17" href="#footnote-17" class="Sup">†</a><br>%</th>
<th class="Rrule" align="center" colspan="2">n = 1080<br>%</th>
<th class="Rrule" align="center" colspan="2">n = 766<br>%</th>
<th align="center" colspan="2">n = 115<br>%</th>
</tr>
<tr class="Last">
<th class="Rrule" align="center" colspan="2">Severe Total</th>
<th class="Rrule" align="center" colspan="2">Severe Total</th>
<th class="Rrule" align="center" colspan="2">Severe Total</th>
<th class="Rrule" align="center" colspan="2">Severe Total</th>
<th align="center" colspan="2">Severe Total</th>
</tr>
</thead>
<tfoot><tr><td colspan="11" align="left"><dl class="Footnote">
<dt><a name="footnote-16" href="#footnote-reference-16">*</a></dt>
<dd>Data represent Lovenox 40 mg SC once a day initiated up to 12 hours prior to surgery in 288 hip replacement surgery patients who received Lovenox peri-operatively in an unblinded fashion in one clinical trial.</dd>
<dt><a name="footnote-17" href="#footnote-reference-17">†</a></dt>
<dd>Data represent Lovenox 40 mg SC once a day given in a blinded fashion as extended prophylaxis at the end of the peri-operative period in 131 of the original 288 hip replacement surgery patients for up to 21 days in one clinical trial.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span></td>
<td align="center">0</td>
<td class="Rrule" align="center">8</td>
<td align="center">0</td>
<td class="Rrule" align="center">0</td>
<td align="center">&lt;1</td>
<td class="Rrule" align="center">5</td>
<td align="center">&lt;1</td>
<td class="Rrule" align="center">4</td>
<td align="center">0</td>
<td align="center">3</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Hemorrhage</span></td>
<td align="center">&lt;1</td>
<td class="Rrule" align="center">13</td>
<td align="center">0</td>
<td class="Rrule" align="center">5</td>
<td align="center">&lt;1</td>
<td class="Rrule" align="center">4</td>
<td align="center">1</td>
<td class="Rrule" align="center">4</td>
<td align="center">0</td>
<td align="center">3</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td align="center"></td>
<td class="Rrule" align="center"></td>
<td align="center"></td>
<td class="Rrule" align="center"></td>
<td align="center">&lt;1</td>
<td class="Rrule" align="center">3</td>
<td align="center">&lt;1</td>
<td class="Rrule" align="center">2</td>
<td align="center">0</td>
<td align="center">2</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span></td>
<td align="center">0</td>
<td class="Rrule" align="center">16</td>
<td align="center">0</td>
<td class="Rrule" align="center">&lt;2</td>
<td align="center">&lt;1</td>
<td class="Rrule" align="center">2</td>
<td align="center">2</td>
<td class="Rrule" align="center">5</td>
<td align="center">&lt;1</td>
<td align="center">7</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span></td>
<td align="center"></td>
<td class="Rrule" align="center"></td>
<td align="center"></td>
<td class="Rrule" align="center"></td>
<td align="center">&lt;1</td>
<td class="Rrule" align="center">2</td>
<td align="center">&lt;1</td>
<td class="Rrule" align="center">2</td>
<td align="center">0</td>
<td align="center">2</td>
</tr>
<tr class="Last">
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">Peripheral edema</span></td>
<td align="center">0</td>
<td class="Rrule" align="center">6</td>
<td align="center">0</td>
<td class="Rrule" align="center">0</td>
<td align="center">&lt;1</td>
<td class="Rrule" align="center">3</td>
<td align="center">&lt;1</td>
<td class="Rrule" align="center">4</td>
<td align="center">0</td>
<td align="center">3</td>
</tr>
</tbody>
</table>
<table width="100%">
<caption><span>Table 10 Adverse Reactions Occurring at ≥2% Incidence in Lovenox-Treated Medical Patients with Severely Restricted Mobility During Acute Illness</span></caption>
<col align="left" valign="top" width="40%">
<col align="center" valign="top" width="30%">
<col align="center" valign="top" width="30%">
<thead>
<tr class="Botrule First">
<th class="Rrule" align="left" rowspan="2" valign="bottom">Adverse Reaction</th>
<th align="center" colspan="2">Dosing Regimen</th>
</tr>
<tr class="Last">
<th class="Rrule" align="center">
<span class="Underline">Lovenox</span><br>40 mg q.d. SC<br>n = 360<br>%</th>
<th align="center">
<span class="Underline">Placebo</span><br>q.d. SC<br>n = 362<br>%</th>
</tr>
</thead>
<tbody>
<tr class="Botrule First">
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Dyspnea</span></td>
<td class="Rrule" align="center">3.3</td>
<td align="center">5.2</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span></td>
<td class="Rrule" align="center">2.8</td>
<td align="center">2.8</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">Confusion</span></td>
<td class="Rrule" align="center">2.2</td>
<td align="center">1.1</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td class="Rrule" align="center">2.2</td>
<td align="center">1.7</td>
</tr>
<tr class="Last">
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td class="Rrule" align="center">2.5</td>
<td align="center">1.7</td>
</tr>
</tbody>
</table>
<table width="100%">
<caption><span>Table 11 Adverse Reactions Occurring at ≥2% Incidence in Lovenox-Treated Patients Undergoing Treatment of <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">Deep Vein Thrombosis</span> with or without <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">Pulmonary Embolism</span></span></caption>
<col align="left" valign="top" width="25%">
<col align="center" valign="top" width="12%">
<col align="center" valign="top" width="13%">
<col align="center" valign="top" width="12%">
<col align="center" valign="top" width="13%">
<col align="center" valign="top" width="12%">
<col align="center" valign="top" width="13%">
<thead>
<tr class="Botrule First">
<th class="Rrule" align="left" rowspan="4" valign="bottom">Adverse Reaction</th>
<th align="center" colspan="6">Dosing Regimen</th>
</tr>
<tr>
<th class="Rrule" align="center" colspan="2">
<span class="Underline">Lovenox</span><br>1.5 mg/kg q.d. SC</th>
<th class="Rrule" align="center" colspan="2">
<span class="Underline">Lovenox</span><br>1 mg/kg q12h SC</th>
<th align="center" colspan="2">
<span class="Underline">Heparin</span><br>aPTT Adjusted IV Therapy</th>
</tr>
<tr>
<th class="Rrule" align="center" colspan="2">n = 298<br>%</th>
<th class="Rrule" align="center" colspan="2">n = 559<br>%</th>
<th align="center" colspan="2">n = 544<br>%</th>
</tr>
<tr class="Last">
<th align="center">Severe</th>
<th class="Rrule" align="center">Total</th>
<th align="center">Severe</th>
<th class="Rrule" align="center">Total</th>
<th align="center">Severe</th>
<th align="center">Total</th>
</tr>
</thead>
<tbody>
<tr class="Botrule First">
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4316205" conceptname="Injection site hemorrhage">Injection Site Hemorrhage</span></td>
<td align="center">0</td>
<td class="Rrule" align="center">5</td>
<td align="center">0</td>
<td class="Rrule" align="center">3</td>
<td align="center">&lt;1</td>
<td align="center">&lt;1</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4316207" conceptname="Injection site pain">Injection Site Pain</span></td>
<td align="center">0</td>
<td class="Rrule" align="center">2</td>
<td align="center">0</td>
<td class="Rrule" align="center">2</td>
<td align="center">0</td>
<td align="center">0</td>
</tr>
<tr class="Last">
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">Hematuria</span></td>
<td align="center">0</td>
<td class="Rrule" align="center">2</td>
<td align="center">0</td>
<td class="Rrule" align="center">&lt;1</td>
<td align="center">&lt;1</td>
<td align="center">2</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.3.2"></a><p></p>
<p class="First"><span class="Bold">Adverse Events in Lovenox-Treated Patients with <span class="product-label-link" type="condition" conceptid="315296" conceptname="Preinfarction syndrome">Unstable Angina</span> or Non-Q-Wave <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Myocardial Infarction</span>:</span></p>
<p>Non-hemorrhagic clinical events reported to be related to Lovenox therapy occurred at an incidence of ≤1%.</p>
<p>Non-major hemorrhagic events, primarily injection site <span class="product-label-link" type="condition" conceptid="4118793" conceptname="Ecchymosis">ecchymoses</span> and <span class="product-label-link" type="condition" conceptid="4147001" conceptname="Hematoma">hematomas</span>, were more frequently reported in patients treated with SC Lovenox than in patients treated with IV heparin.</p>
<p>Serious adverse events with Lovenox or heparin in a clinical trial in patients with <span class="product-label-link" type="condition" conceptid="315296" conceptname="Preinfarction syndrome">unstable angina</span> or non-Q-wave <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> that occurred at a rate of at least 0.5% in the Lovenox group are provided below [see<a href="#table12"> Table 12</a>].</p>
<a name="table12"></a><table width="100%">
<caption><span>Table 12 Serious Adverse Events Occurring at ≥0.5% Incidence in Lovenox-Treated Patients with <span class="product-label-link" type="condition" conceptid="315296" conceptname="Preinfarction syndrome">Unstable Angina</span> or Non-Q-Wave <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Myocardial Infarction</span></span></caption>
<col align="left" valign="top" width="40%">
<col align="center" valign="top" width="30%">
<col align="center" valign="top" width="30%">
<thead>
<tr class="Botrule First">
<th class="Rrule" align="left" rowspan="3" valign="bottom">Adverse Event</th>
<th align="center" colspan="2">Dosing Regimen</th>
</tr>
<tr>
<th class="Rrule" align="center">
<span class="Underline">Lovenox</span><br>1 mg/kg q12h SC</th>
<th align="center">
<span class="Underline">Heparin</span><br>aPTT Adjusted IV Therapy</th>
</tr>
<tr class="Last">
<th class="Rrule" align="center">n = 1578<br>n (%)</th>
<th align="center">n = 1529<br>n (%)</th>
</tr>
</thead>
<tbody>
<tr class="Botrule First">
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">Atrial fibrillation</span></td>
<td class="Rrule" align="center">11 (0.70)</td>
<td align="center">3 (0.20)</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Heart failure</span></td>
<td class="Rrule" align="center">15 (0.95)</td>
<td align="center">11 (0.72)</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">Lung edema</span></td>
<td class="Rrule" align="center">11 (0.70)</td>
<td align="center">11 (0.72)</td>
</tr>
<tr class="Last">
<td class="Rrule" align="left"><span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Pneumonia</span></td>
<td class="Rrule" align="center">13 (0.82)</td>
<td align="center">9 (0.59)</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.3.3"></a><p></p>
<p class="First"><span class="Bold">Adverse Reactions in Lovenox-Treated Patients with Acute ST-Segment Elevation <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Myocardial Infarction</span>:</span></p>
<p>In a clinical trial in patients with acute ST-segment elevation <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, the only adverse reaction that occurred at a rate of at least 0.5% in the Lovenox group was <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> (1.5%).</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.2"></a><a name="section-6.2"></a><p></p>
<h2>6.2 Postmarketing Experience </h2>
<p class="First">The following adverse reactions have been identified during postapproval use of Lovenox. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</p>
<p>There have been reports of epidural or spinal <span class="product-label-link" type="condition" conceptid="4147001" conceptname="Hematoma">hematoma</span> formation with concurrent use of Lovenox and spinal/epidural anesthesia or spinal puncture. The majority of patients had a post-operative indwelling epidural catheter placed for <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> or received additional drugs affecting hemostasis such as NSAIDs. Many of the epidural or spinal <span class="product-label-link" type="condition" conceptid="4147001" conceptname="Hematoma">hematomas</span> caused neurologic injury, including long-term or permanent <span class="product-label-link" type="condition" conceptid="440377" conceptname="Paralysis">paralysis</span>.</p>
<p>Local reactions at the injection site (<span class="Italics">e.g.</span> <span class="product-label-link" type="condition" conceptid="4101098" conceptname="Nodule">nodules</span>, <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span>, oozing), <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">systemic allergic reactions</span> (<span class="Italics">e.g.</span> <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span><span class="Italics">,</span> anaphylactic/<span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span> including <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span>), <span class="product-label-link" type="condition" conceptid="4032934" conceptname="Vesiculobullous rash">vesiculobullous rash</span>, rare cases of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> <span class="product-label-link" type="condition" conceptid="4182711" conceptname="Vasculitis of the skin">cutaneous vasculitis</span>, <span class="product-label-link" type="condition" conceptid="4047773" conceptname="Purpura">purpura</span>, <span class="product-label-link" type="condition" conceptid="4317266" conceptname="Skin necrosis">skin necrosis</span> (occurring at either the injection site or distant from the injection site), <span class="product-label-link" type="condition" conceptid="4280071" conceptname="Thrombocytosis">thrombocytosis</span>, and <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> with <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span> [see<span class="Italics"><a href="#S5.5"> Warnings and Precautions (5.5)</a></span>] have been reported.</p>
<p>Cases of <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> have been reported. Most of these reports occurred in patients who also had conditions that tend toward the development of <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> (<span class="Italics">e.g.</span>, renal dysfunction, concomitant potassium-sparing drugs, administration of potassium, <span class="product-label-link" type="condition" conceptid="4147001" conceptname="Hematoma">hematoma</span> in body tissues). Very rare cases of <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipidemia</span> have also been reported, with one case of <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipidemia</span>, with marked <span class="product-label-link" type="condition" conceptid="440360" conceptname="Pure hyperglyceridemia">hypertriglyceridemia</span>, reported in a diabetic pregnant woman; causality has not been determined.</p>
<p>Cases of <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="434894" conceptname="Acute posthemorrhagic anemia">hemorrhagic anemia</span>, <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>, <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>, hepatocellular and cholestatic <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver injury</span> have been reported.</p>
<p><span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">Osteoporosis</span> has also been reported following long-term therapy.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="S7"></a><a name="section-7"></a><p></p>
<h1>7	DRUG INTERACTIONS</h1>
<p class="First">Whenever possible, agents which may enhance the risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span> should be discontinued prior to initiation of Lovenox therapy. These agents include medications such as: anticoagulants, platelet inhibitors including acetylsalicylic acid, salicylates, NSAIDs (including ketorolac tromethamine), dipyridamole, or sulfinpyrazone. If co-administration is essential, conduct close clinical and laboratory monitoring [see<span class="Italics"><a href="#S5.9"> Warnings and Precautions (5.9)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="S8"></a><a name="section-8"></a><p></p>
<h1>8	USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="S8.1"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="section-8.1.1"></a><p></p>
<p class="First"><span class="Italics Underline">Pregnancy Category B</span></p>
<p>All pregnancies have a background risk of birth defect, loss, or other adverse outcome regardless of drug exposure. The fetal risk summary below describes the potential of Lovenox to increase the risk of developmental abnormalities above the background risk.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.1.2"></a><p></p>
<p class="First"><span class="Italics"><span class="Underline">Fetal Risk Summary</span></span></p>
<p>Lovenox does not cross the placenta, and is not expected to result in fetal exposure to the drug. Human data from a retrospective cohort study, which included 693 live births, suggest that Lovenox does not increase the risk of major developmental abnormalities. Based on animal data, enoxaparin is not predicted to increase the risk of major developmental abnormalities (see <span class="Italics"><a href="#data">Data</a></span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.1.3"></a><p></p>
<p class="First"><span class="Italics"><span class="Underline">Clinical Considerations</span></span></p>
<p>Pregnancy alone confers an increased risk for <span class="product-label-link" type="condition" conceptid="4159647" conceptname="Thromboembolic disorder">thromboembolism</span> that is even higher for women with thromboembolic disease and certain high risk pregnancy conditions. While not adequately studied, pregnant women with mechanical prosthetic heart valves may be at even higher risk for <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span> [see<span class="Italics"><a href="#S5.7"> Warnings and Precautions (5.7)</a></span> and<span class="Italics"><a href="#S8.6"> Use in Specific Populations (8.6)</a></span>]. Pregnant women with thromboembolic disease, including those with mechanical prosthetic heart valves and those with inherited or acquired <span class="product-label-link" type="condition" conceptid="4125650" conceptname="Thrombophilia">thrombophilias</span>, have an increased risk of other maternal complications and fetal loss regardless of the type of anticoagulant used.</p>
<p>All patients receiving anticoagulants, including pregnant women, are at risk for <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. Pregnant women receiving enoxaparin should be carefully monitored for evidence of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> or excessive anticoagulation. Consideration for use of a shorter acting anticoagulant should be specifically addressed as delivery approaches [see<span class="Italics"><a href="#BOX"> Boxed Warning</a></span>]. <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Hemorrhage</span> can occur at any site and may lead to <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> of mother and/or fetus. Pregnant women should be apprised of the potential hazard to the fetus and the mother if enoxaparin is administered during pregnancy.</p>
<p>It is not known if monitoring of anti-Factor Xa activity and dose adjustment (by weight or anti-Factor Xa activity) of Lovenox affect the safety and the efficacy of the drug during pregnancy.</p>
<p>Cases of "<span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">gasping</span> syndrome" have occurred in premature infants when large amounts of benzyl alcohol have been administered (99–405 mg/kg/day). The multiple-dose vial of Lovenox contains 15 mg benzyl alcohol per 1 mL as a preservative [see<span class="Italics"><a href="#S5.8"> Warnings and Precautions (5.8)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="data"></a><a name="section-8.1.4"></a><p></p>
<p class="First"><span class="Italics"><span class="Underline">Data</span></span></p>
<ul class="Disc">
<li>
<span class="Italics">Human Data</span><span class="Italics"> - </span>There are no   adequate and well-controlled studies in pregnant women. A retrospective   study reviewed the records of 604 women who used enoxaparin during   pregnancy. A total of 624 pregnancies resulted in 693 live births. There were   72 hemorrhagic events (11 serious) in 63 women. There were 14 cases of   neonatal <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>. Major congenital anomalies in live births occurred at   rates (2.5%) similar to background rates.<br><br>There have been postmarketing reports of <span class="product-label-link" type="condition" conceptid="4079844" conceptname="Fetal death">fetal death</span> when pregnant women received Lovenox. Causality for these cases has not been determined. Insufficient data, the underlying disease, and the possibility of inadequate anticoagulation complicate the evaluation of these cases.<br><br>A clinical study using enoxaparin in pregnant women with mechanical prosthetic heart valves has been conducted [see <span class="Italics"><a href="#S5.7">Warnings and Precautions (5.7)</a></span>].<br> </li>
<li>
<span class="Italics">Animal Data - </span>Teratology   studies have been conducted in pregnant rats and rabbits at SC doses of   enoxaparin up to 15 times the recommended human dose (by comparison with 2   mg/kg as the maximum recommended daily dose). There was no evidence of   teratogenic effects or fetotoxicity due to enoxaparin. Because animal   reproduction studies are not always predictive of human response, this   drug should be used during pregnancy only if clearly needed.</li>
</ul>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="S8.3"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">It is not known whether Lovenox is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from Lovenox, a decision should be made whether to discontinue nursing or discontinue Lovenox, taking into account the importance of Lovenox to the mother and the known benefits of nursing.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="S8.4"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">Safety and effectiveness of Lovenox in pediatric patients have not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="S8.5"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.4.1"></a><p></p>
<p class="First"><span class="Italics"><span class="Underline">Prevention of <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">Deep Vein Thrombosis</span> in Hip, Knee and Abdominal Surgery; Treatment of <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">Deep Vein Thrombosis</span>, Prevention of Ischemic Complications of <span class="product-label-link" type="condition" conceptid="315296" conceptname="Preinfarction syndrome">Unstable Angina</span> and Non-Q-wave <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Myocardial Infarction</span></span></span></p>
<p>Over 2800 patients, 65 years and older, have received Lovenox in pivotal clinical trials. The efficacy of Lovenox in the geriatric (≥65 years) was similar to that seen in younger patients (&lt;65 years). The incidence of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> complications was similar between geriatric and younger patients when 30 mg every 12 hours or 40 mg once a day doses of Lovenox were employed. The incidence of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> complications was higher in geriatric patients as compared to younger patients when Lovenox was administered at doses of 1.5 mg/kg once a day or 1 mg/kg every 12 hours. The risk of Lovenox-associated <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> increased with age. Serious adverse events increased with age for patients receiving Lovenox. Other clinical experience (including postmarketing surveillance and literature reports) has not revealed additional differences in the safety of Lovenox between geriatric and younger patients. Careful attention to dosing intervals and concomitant medications (especially antiplatelet medications) is advised. Lovenox should be used with care in geriatric patients who may show delayed elimination of enoxaparin. Monitoring of geriatric patients with low body weight (&lt;45 kg) and those predisposed to decreased renal function should be considered [see<span class="Italics"><a href="#S5.9"> Warnings and Precautions (5.9) </a>and<a href="#S12.3"> Clinical Pharmacology (12.3)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.4.2"></a><p></p>
<p class="First"><span class="Italics"><span class="Underline">Treatment of Acute ST-Segment Elevation <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Myocardial Infarction</span></span></span></p>
<p>In the clinical study for treatment of acute ST-segment elevation <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, there was no evidence of difference in efficacy between patients ≥75  years of age (n = 1241) and patients less than 75 years of age (n=9015). Patients ≥75  years of age did not receive a 30 mg IV bolus prior to the normal dosage regimen and had their SC dose adjusted to 0.75 mg/kg every 12 hours [see <span class="Italics"><a href="#S2.3">Dosage and Administration (2.3)</a></span>]. The incidence of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> complications was higher in patients ≥65 years of age as compared to younger patients (&lt;65 years).</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S8.6"></a><a name="section-8.5"></a><p></p>
<h2>8.6 Patients with Mechanical Prosthetic Heart Valves</h2>
<p class="First">The use of Lovenox has not been adequately studied for thromboprophylaxis in patients with mechanical prosthetic heart valves and has not been adequately studied for long-term use in this patient population. Isolated cases of prosthetic heart valve <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span> have been reported in patients with mechanical prosthetic heart valves who have received enoxaparin for thromboprophylaxis. Some of these cases were pregnant women in whom <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">thrombosis</span> led to maternal and <span class="product-label-link" type="condition" conceptid="4079844" conceptname="Fetal death">fetal deaths</span>. Insufficient data, the underlying disease and the possibility of inadequate anticoagulation complicate the evaluation of these cases. Pregnant women with mechanical prosthetic heart valves may be at higher risk for <span class="product-label-link" type="condition" conceptid="4159647" conceptname="Thromboembolic disorder">thromboembolism</span> [see<span class="Italics"><a href="#S5.7"> Warnings and Precautions (5.7)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S8.7"></a><a name="section-8.6"></a><p></p>
<h2>8.7 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">In patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, there is an increase in exposure of enoxaparin sodium. All such patients should be observed carefully for signs and symptoms of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. Because exposure of enoxaparin sodium is significantly increased in patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (creatinine clearance &lt;30 mL/min), a dosage adjustment is recommended for therapeutic and <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> dosage ranges. No dosage adjustment is recommended in patients with moderate (creatinine clearance 30–50 mL/min) and mild (creatinine clearance 50–80 mL/min) <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> [see <span class="Italics"><a href="#S2.2">Dosage and Administration (2.2)</a></span> and<span class="Italics"><a href="#S12.3"> Clinical Pharmacology (12.3)</a></span>]. In patients with <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>, treatment with enoxaparin has been associated with the development of <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span> [see <span class="Italics"><a href="#S6.2">Adverse Reactions (6.2)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S8.8"></a><a name="section-8.7"></a><p></p>
<h2>8.8 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">The impact of <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> on enoxaparin's exposure and antithrombotic effect has not been investigated. Caution should be exercised when administering enoxaparin to patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S8.9"></a><a name="section-8.8"></a><p></p>
<h2>8.9 Low-Weight Patients</h2>
<p class="First">An increase in exposure of enoxaparin sodium with <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> dosages (non-weight adjusted) has been observed in low-weight women (&lt;45 kg) and low-weight men (&lt;57 kg). All such patients should be observed carefully for signs and symptoms of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> [see <span class="Italics"><a href="#S12.3">Clinical Pharmacology (12.3)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S8.10"></a><a name="section-8.9"></a><p></p>
<h2>8.10 Obese Patients</h2>
<p class="First">Obese patients are at higher risk for <span class="product-label-link" type="condition" conceptid="4159647" conceptname="Thromboembolic disorder">thromboembolism</span>. The safety and efficacy of <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> doses of Lovenox in obese patients (BMI &gt;30 kg/m<span class="Sup">2</span>) has not been fully determined and there is no consensus for dose adjustment.  These patients should be observed carefully for signs and symptoms of <span class="product-label-link" type="condition" conceptid="4159647" conceptname="Thromboembolic disorder">thromboembolism</span>. </p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="S10"></a><a name="section-9"></a><p></p>
<h1>10	OVERDOSAGE</h1>
<p class="First">Accidental overdosage following administration of Lovenox may lead to hemorrhagic complications. Injected Lovenox may be largely neutralized by the slow IV injection of protamine sulfate (1% solution). The dose of protamine sulfate should be equal to the dose of Lovenox injected: 1 mg protamine sulfate should be administered to neutralize 1 mg Lovenox, if enoxaparin sodium was administered in the previous 8 hours. An infusion of 0.5 mg protamine per 1 mg of enoxaparin sodium may be administered if enoxaparin sodium was administered greater than 8 hours previous to the protamine administration, or if it has been determined that a second dose of protamine is required. The second infusion of 0.5 mg protamine sulfate per 1 mg of Lovenox may be administered if the aPTT measured 2 to 4 hours after the first infusion remains prolonged.</p>
<p>If at least 12 hours have elapsed since the last enoxaparin sodium injection, protamine administration may not be required; however, even with higher doses of protamine, the aPTT may remain more prolonged than following administration of heparin. In all cases, the anti-Factor Xa activity is never completely neutralized (maximum about 60%). Particular care should be taken to avoid overdosage with protamine sulfate. Administration of protamine sulfate can cause severe hypotensive and <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span>. Because fatal reactions, often resembling <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, have been reported with protamine sulfate, it should be given only when resuscitation techniques and treatment of <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic shock</span> are readily available. For additional information consult the labeling of protamine sulfate injection products.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="S11"></a><a name="section-10"></a><p></p>
<h1>11	DESCRIPTION</h1>
<p class="First">Lovenox is a sterile aqueous solution containing enoxaparin sodium, a low molecular weight heparin. The pH of the injection is 5.5 to 7.5.</p>
<p>Enoxaparin sodium is obtained by alkaline depolymerization of heparin benzyl ester derived from porcine intestinal mucosa. Its structure is characterized by a 2-O-sulfo-4-enepyranosuronic acid group at the non-reducing end and a 2-N,6-O-disulfo-D-glucosamine at the reducing end of the chain. About 20% (ranging between 15% and 25%) of the enoxaparin structure contains an 1,6 anhydro derivative on the reducing end of the polysaccharide chain. The drug substance is the sodium salt. The average molecular weight is about 4500 daltons. The molecular weight distribution is:</p>
<table width="50%">
<col align="left" valign="top" width="50%">
<col align="left" valign="top" width="50%">
<tbody class="Headless">
<tr class="First Toprule">
<td align="left">&lt;2000 daltons</td>
<td align="left">≤20%</td>
</tr>
<tr>
<td align="left">2000 to 8000 daltons</td>
<td align="left">≥68%</td>
</tr>
<tr class="Botrule Last">
<td align="left">&gt;8000 daltons</td>
<td align="left">≤18%</td>
</tr>
</tbody>
</table>
<p>STRUCTURAL FORMULA</p>
<p><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=53fd1302-9e1b-4e04-b06d-1a706547c388&amp;name=lovenoxnovaplus-06.jpg"></p>
<table width="75%">
<col align="center" valign="middle" width="10%">
<col align="center" valign="middle" width="30%">
<col align="center" valign="middle" width="40%">
<col align="center" valign="middle" width="20%">
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-18" href="#footnote-reference-18">*</a></dt>
<dd>X = Percent of polysaccharide chain containing 1,6 anhydro derivative on the reducing end.</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="Botrule First">
<td class="Lrule Rrule" align="center" rowspan="2"><span class="Bold">R</span></td>
<td class="Rrule" align="center"><span class="Bold">X<a name="footnote-reference-18" href="#footnote-18" class="Sup">*</a>= 15 to 25%</span></td>
<td class="Rrule" align="center"><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=53fd1302-9e1b-4e04-b06d-1a706547c388&amp;name=lovenoxnovaplus-07.jpg"></td>
<td class="Rrule" align="center"><span class="Bold">n= 0 to 20</span></td>
</tr>
<tr class="Last">
<td class="Rrule" align="center"><span class="Bold">100 - X</span></td>
<td class="Rrule" align="center"><span class="Bold">H</span></td>
<td class="Rrule" align="center"><span class="Bold">n =1 to 21</span></td>
</tr>
</tbody>
</table>
<p><span class="Bold">Lovenox 100 mg/mL Concentration</span> contains 10 mg enoxaparin sodium (approximate anti-Factor Xa activity of 1000 IU [with reference to the W.H.O. First International Low Molecular Weight Heparin Reference Standard]) per 0.1 mL Water for Injection.</p>
<p><span class="Bold">Lovenox 150 mg/mL Concentration </span>contains 15 mg enoxaparin sodium (approximate anti-Factor Xa activity of 1500 IU [with reference to the W.H.O. First International Low Molecular Weight Heparin Reference Standard]) per 0.1 mL Water for Injection.</p>
<p>The Lovenox prefilled syringes and graduated prefilled syringes are preservative-free and intended for use only as a single-dose injection. The multiple-dose vial contains 15 mg benzyl alcohol per 1 mL as a preservative [see <span class="Italics"><a href="#S2">Dosage and Administration (2)</a></span> and<span class="Italics"><a href="#S16"> How Supplied (16)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="S12"></a><a name="section-11"></a><p></p>
<h1>12	CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="S12.1"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">Enoxaparin is a low molecular weight heparin which has antithrombotic properties.</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="S12.2"></a><a name="section-11.2"></a><p></p>
<h2>12.2 Pharmacodynamics</h2>
<p class="First">In humans, enoxaparin given at a dose of 1.5 mg/kg subcutaneously (SC) is characterized by a higher ratio of anti-Factor Xa to anti-Factor IIa activity (mean ± SD, 14.0 ± 3.1) (based on areas under anti-Factor activity versus time curves) compared to the ratios observed for heparin (mean±SD, 1.22 ± 0.13). Increases of up to 1.8 times the control values were seen in the <span class="product-label-link" type="condition" conceptid="4208541" conceptname="Thrombin time">thrombin time</span> (TT) and the <span class="product-label-link" type="condition" conceptid="44809202" conceptname="Activated partial thromboplastin time">activated partial thromboplastin time</span> (aPTT). Enoxaparin at a 1 mg/kg dose (100 mg/mL concentration), administered SC every 12 hours to patients in a large clinical trial resulted in aPTT values of 45 seconds or less in the majority of patients (n = 1607). A 30 mg IV bolus immediately followed by a 1 mg/kg SC administration resulted in aPTT post-injection values of 50 seconds. The average aPTT prolongation value on Day 1 was about 16% higher than on Day 4.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="S12.3"></a><a name="section-11.3"></a><p></p>
<h2>12.3 Pharmacokinetics </h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.1"></a><p></p>
<p class="First"><span class="Italics"><span class="Underline">Absorption:</span></span> Pharmacokinetic trials were conducted using the 100 mg/mL formulation. Maximum anti-Factor Xa and anti-thrombin (anti-Factor IIa) activities occur 3 to 5 hours after SC injection of enoxaparin. Mean peak anti-Factor Xa activity was 0.16 IU/mL (1.58 mcg/mL) and 0.38 IU/mL (3.83 mcg/mL) after the 20 mg and the 40 mg clinically tested SC doses, respectively. Mean (n = 46) peak anti-Factor Xa activity was 1.1 IU/mL at steady state in patients with <span class="product-label-link" type="condition" conceptid="315296" conceptname="Preinfarction syndrome">unstable angina</span> receiving 1 mg/kg SC every 12 hours for 14 days. Mean absolute bioavailability of enoxaparin, after 1.5 mg/kg given SC, based on anti-Factor Xa activity is approximately 100% in healthy subjects.</p>
<p>A 30 mg IV bolus immediately followed by a 1 mg/kg SC every 12 hours provided initial peak anti-Factor Xa levels of 1.16 IU/mL (n=16) and average exposure corresponding to 84% of steady-state levels. Steady state is achieved on the second day of treatment.</p>
<p>Enoxaparin pharmacokinetics appear to be linear over the recommended dosage ranges [see<span class="Italics"><a href="#S2"> Dosage and Administration (2)</a></span>]. After repeated subcutaneous administration of 40 mg once daily and 1.5 mg/kg once-daily regimens in healthy volunteers, the steady state is reached on day 2 with an average exposure ratio about 15% higher than after a single dose. Steady-state enoxaparin activity levels are well predicted by single-dose pharmacokinetics. After repeated subcutaneous administration of the 1 mg/kg twice daily regimen, the steady state is reached from day 4 with mean exposure about 65% higher than after a single dose and mean peak and trough levels of about 1.2 and 0.52 IU/mL, respectively. Based on enoxaparin sodium pharmacokinetics, this difference in steady state is expected and within the therapeutic range.</p>
<p>Although not studied clinically, the 150 mg/mL concentration of enoxaparin sodium is projected to result in anticoagulant activities similar to those of 100 mg/mL and 200 mg/mL concentrations at the same enoxaparin dose. When a daily 1.5 mg/kg SC injection of enoxaparin sodium was given to 25 healthy male and female subjects using a 100 mg/mL or a 200 mg/mL concentration the following pharmacokinetic profiles were obtained [see<a href="#table13"> Table 13</a>].</p>
<a name="table13"></a><table width="100%">
<caption><span>Table 13 Pharmacokinetic Parameters<a name="footnote-reference-19" href="#footnote-19" class="Sup">*</a> After 5 Days of 1.5 mg/kg SC Once Daily Doses of  Enoxaparin Sodium Using 100 mg/mL or 200 mg/mL Concentrations</span></caption>
<col align="left" valign="top" width="16%">
<col align="center" valign="top" width="17%">
<col align="center" valign="top" width="17%">
<col align="center" valign="top" width="17%">
<col align="center" valign="top" width="17%">
<col align="center" valign="top" width="16%">
<thead><tr class="First Last">
<th class="Rrule" align="left"></th>
<th class="Rrule" align="center">Concentration</th>
<th class="Rrule" align="center">Anti-Xa</th>
<th class="Rrule" align="center">Anti-IIa</th>
<th class="Rrule" align="center">Heptest</th>
<th align="center">aPTT</th>
</tr></thead>
<tfoot><tr><td colspan="6" align="left"><dl class="Footnote">
<dt><a name="footnote-19" href="#footnote-reference-19">*</a></dt>
<dd>Means ± SD at Day 5 and 90% Confidence Interval (CI) of the ratio</dd>
<dt><a name="footnote-20" href="#footnote-reference-20">†</a></dt>
<dd>Median (range)</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Rrule" align="left" rowspan="3">
<span class="Bold">A<span class="Sub">max</span></span><br>(IU/mL or Δ sec)</td>
<td class="Rrule" align="center" valign="middle">100 mg/mL</td>
<td class="Rrule" align="center" valign="middle">1.37 (<span class="Sup">±</span>0.23)</td>
<td class="Rrule" align="center" valign="middle">0.23 (<span class="Sup">±</span>0.05)</td>
<td class="Rrule" align="center" valign="middle">105 (<span class="Sup">±</span>17)</td>
<td align="center" valign="middle">19 (<span class="Sup">±</span>5)</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="center">200 mg/mL</td>
<td class="Rrule" align="center">1.45 (<span class="Sup">±</span>0.22)</td>
<td class="Rrule" align="center">0.26 (<span class="Sup">±</span>0.05)</td>
<td class="Rrule" align="center">111 (<span class="Sup">±</span>17)</td>
<td align="center">22 (<span class="Sup">±</span>7)</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="center">90% CI</td>
<td class="Rrule" align="center">102–110%</td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center">102–111%</td>
<td align="center"></td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left" rowspan="2">
<span class="Bold">t<span class="Sub">max</span></span><a name="footnote-reference-20" href="#footnote-20" class="Sup">†</a> (h)</td>
<td class="Rrule" align="center">100 mg/mL</td>
<td class="Rrule" align="center">3 (2–6)</td>
<td class="Rrule" align="center">4 (2–5)</td>
<td class="Rrule" align="center">2.5 (2–4.5)</td>
<td align="center">3 (2–4.5)</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="center">200 mg/mL</td>
<td class="Rrule" align="center">3.5 (2–6)</td>
<td class="Rrule" align="center">4.5 (2.5–6)</td>
<td class="Rrule" align="center">3.3 (2–5)</td>
<td align="center">3 (2–5)</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left" rowspan="3">
<span class="Bold">AUC  </span>(ss)<br>(h<a href="#footnote-19" class="Sup">*</a>IU/mL or h<a href="#footnote-19" class="Sup">*</a> Δ sec)</td>
<td class="Rrule" align="center" valign="middle">100 mg/mL</td>
<td class="Rrule" align="center" valign="middle">14.26 (<span class="Sup">±</span>2.93)</td>
<td class="Rrule" align="center" valign="middle">1.54 (<span class="Sup">±</span>0.61)	</td>
<td class="Rrule" align="center" valign="middle">1321 (<span class="Sup">±</span>219)</td>
<td align="center" rowspan="3"></td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="center">200 mg/mL</td>
<td class="Rrule" align="center">15.43 (<span class="Sup">±</span>2.96)</td>
<td class="Rrule" align="center">1.77 (<span class="Sup">±</span>0.67)</td>
<td class="Rrule" align="center">1401 (<span class="Sup">±</span>227)</td>
</tr>
<tr class="Last">
<td class="Rrule" align="center">90% CI</td>
<td class="Rrule" align="center">105–112%</td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center">103–109%</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.2"></a><p></p>
<p class="First"><span class="Italics"><span class="Underline">Distribution</span>: </span>The volume of distribution of anti-Factor Xa activity is about 4.3 L.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.3"></a><p></p>
<p class="First"><span class="Italics"><span class="Underline">Elimination:</span></span> Following intravenous (IV) dosing, the total body clearance of enoxaparin is 26 mL/min. After IV dosing of enoxaparin labeled with the gamma-emitter, <span class="Sup">99m</span>Tc, 40% of radioactivity and 8 to 20% of anti-Factor Xa activity were recovered in urine in 24 hours. Elimination half-life based on anti-Factor Xa activity was 4.5 hours after a single SC dose to about 7 hours after repeated dosing. Significant anti-Factor Xa activity persists in plasma for about 12 hours following a 40 mg SC once a day dose.</p>
<p>Following SC dosing, the apparent clearance (CL/F) of enoxaparin is approximately 15 mL/min.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.4"></a><p></p>
<p class="First"><span class="Italics"><span class="Underline">Metabolism:</span></span> Enoxaparin sodium is primarily metabolized in the liver by desulfation and/or depolymerization to lower molecular weight species with much reduced biological potency. Renal clearance of active fragments represents about 10% of the administered dose and total renal excretion of active and non-active fragments 40% of the dose.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.5"></a><p></p>
<p class="First"><span class="Italics Underline">Special Populations</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.5.1"></a><p></p>
<p class="First"><span class="Italics">Gender: </span>Apparent clearance and A<span class="Sub">max</span> derived from anti-Factor Xa values following single SC dosing (40 mg and 60 mg) were slightly higher in males than in females. The source of the gender difference in these parameters has not been conclusively identified; however, body weight may be a contributing factor.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.5.2"></a><p></p>
<p class="First"><span class="Italics">Geriatric: </span>Apparent clearance and A<span class="Sub">max</span> derived from anti-Factor Xa values following single and multiple SC dosing in geriatric subjects were close to those observed in young subjects. Following once a day SC dosing of 40 mg enoxaparin, the Day 10 mean area under anti-Factor Xa activity versus time curve (AUC) was approximately 15% greater than the mean Day 1 AUC value [see<span class="Italics"><a href="#S2.3"> Dosage and Administration (2.3)</a></span> and<span class="Italics"><a href="#S8.5"> Use in Specific Populations (8.5)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.5.3"></a><p></p>
<p class="First"><span class="Italics"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>:</span> A linear relationship between anti-Factor Xa plasma clearance and creatinine clearance at steady state has been observed, which indicates decreased clearance of enoxaparin sodium in patients with reduced renal function. Anti-Factor Xa exposure represented by AUC, at steady state, is marginally increased in mild (creatinine clearance 50–80 mL/min) and moderate (creatinine clearance 30–50 mL/min) <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> after repeated subcutaneous 40 mg once-daily doses. In patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (creatinine clearance &lt;30 mL/min), the AUC at steady state is significantly increased on average by 65% after repeated subcutaneous 40 mg once-daily doses [see<span class="Italics"><a href="#S2.2"> Dosage and Administration (2.2)</a></span> and<span class="Italics"><a href="#S8.7"> Use in Specific Populations (8.7)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.5.4"></a><p></p>
<p class="First"><span class="Italics">Hemodialysis: </span>In a single study, elimination rate appeared similar but AUC was two-fold higher than control population, after a single 0.25 or 0.5 mg/kg intravenous dose.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.5.5"></a><p></p>
<p class="First"><span class="Italics"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span>:</span> Studies with enoxaparin in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> have not been conducted and the impact of <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> on the exposure to enoxaparin is unknown [see <span class="Italics"><a href="#S8.8">Use in Specific Populations (8.8)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.5.6"></a><p></p>
<p class="First"><span class="Italics">Weight: </span>After repeated subcutaneous 1.5 mg/kg once daily dosing, mean AUC of anti-Factor Xa activity is marginally higher at steady state in obese healthy volunteers (BMI 30–48 kg/m<span class="Sup">2</span>) compared to non-obese control subjects, while A<span class="Sub">max</span> is not increased.</p>
<p>When non-weight adjusted dosing was administered, it was found after a single-subcutaneous 40 mg dose, that anti-Factor Xa exposure is 52% higher in low-weight women (&lt;45 kg) and 27% higher in low-weight men (&lt;57 kg) when compared to normal weight control subjects [see <span class="Italics"><a href="#S8.9">Use in Specific Populations (8.9)</a></span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.3.5.7"></a><p></p>
<p class="First"><span class="Italics"><span class="Underline"><span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">Pharmacokinetic interaction</span>:</span></span> No <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacokinetic interaction</span> was observed between enoxaparin and thrombolytics when administered concomitantly.</p>
</div>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="S13"></a><a name="section-12"></a><p></p>
<h1>13	NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="S13.1"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">No long-term studies in animals have been performed to evaluate the carcinogenic potential of enoxaparin. Enoxaparin was not mutagenic in <span class="Italics">in vitro</span> tests, including the Ames test, mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> cell forward mutation test, and human lymphocyte chromosomal aberration test, and the <span class="Italics">in vivo</span> rat bone marrow chromosomal aberration test. Enoxaparin was found to have no effect on fertility or reproductive performance of male and female rats at SC doses up to 20 mg/kg/day or 141 mg/m<span class="Sup">2</span>/day. The maximum human dose in clinical trials was 2.0 mg/kg/day or 78 mg/m<span class="Sup">2</span>/day (for an average body weight of 70 kg, height of 170 cm, and body surface area of 1.8 m<span class="Sup">2</span>).</p>
</div>
<div class="Section" data-sectionCode="34091-9">
<a name="S13.2"></a><a name="section-12.2"></a><p></p>
<h2>13.2 Animal Toxicology and/or Pharmacology</h2>
<p class="First">A single SC dose of 46.4 mg/kg enoxaparin was lethal to rats. The symptoms of acute toxicity were <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, decreased motility, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="438555" conceptname="Cyanosis">cyanosis</span>, and <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S13.3"></a><a name="section-12.3"></a><p></p>
<h2>13.3 Reproductive and Developmental Toxicology</h2>
<p class="First">Teratology studies have been conducted in pregnant rats and rabbits at SC doses of enoxaparin up to 30 mg/kg/day corresponding to 211 mg/m<span class="Sup">2</span>/day and 410 mg/m<span class="Sup">2</span>/day in rats and rabbits respectively. There was no evidence of teratogenic effects or fetotoxicity due to enoxaparin.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="S14"></a><a name="section-13"></a><p></p>
<h1>14	CLINICAL STUDIES</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S14.1"></a><a name="section-13.1"></a><p></p>
<h2>14.1 Prophylaxis of <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">Deep Vein Thrombosis</span> Following Abdominal Surgery in Patients at Risk for Thromboembolic Complications</h2>
<p class="First">Abdominal surgery patients at risk include those who are over 40 years of age, obese, undergoing surgery under general anesthesia lasting longer than 30 minutes or who have additional risk factors such as malignancy or a history of <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">deep vein thrombosis</span> (DVT) or <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span> (PE).</p>
<p>In a double-blind, parallel group study of patients undergoing elective cancer surgery of the gastrointestinal, urological, or gynecological tract, a total of 1116 patients were enrolled in the study, and 1115 patients were treated. Patients ranged in age from 32 to 97 years (mean age 67 years) with 52.7% men and 47.3% women. Patients were 98% Caucasian, 1.1% Black, 0.4% Asian and 0.4% others. Lovenox 40 mg SC, administered once a day, beginning 2 hours prior to surgery and continuing for a maximum of 12 days after surgery, was comparable to heparin 5000 U every 8 hours SC in reducing the risk of DVT. The efficacy data are provided below [see<a href="#table14"> Table 14</a>].</p>
<a name="table14"></a><table width="100%">
<caption><span>Table 14 Efficacy of Lovenox in the Prophylaxis of <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">Deep Vein Thrombosis</span> Following Abdominal Surgery</span></caption>
<col align="left" valign="top" width="33%">
<col align="center" valign="top" width="34%">
<col align="center" valign="top" width="33%">
<thead>
<tr class="Botrule First">
<th class="Rrule" align="left" rowspan="2" valign="bottom">Indication</th>
<th align="center" colspan="2">Dosing Regimen</th>
</tr>
<tr class="Last">
<th class="Rrule" align="center">
<span class="Underline">Lovenox</span><br>40 mg q.d. SC<br>n (%)</th>
<th align="center">
<span class="Underline">Heparin</span><br>5000 U q8h SC<br>n (%)</th>
</tr>
</thead>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-21" href="#footnote-reference-21">*</a></dt>
<dd>VTE = Venous <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">thromboembolic events</span> which included DVT, PE, and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> considered to be thromboembolic in origin</dd>
<dt><a name="footnote-22" href="#footnote-reference-22">†</a></dt>
<dd>CI = Confidence Interval</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Rrule" align="left">All Treated Abdominal Surgery Patients</td>
<td class="Rrule" align="center">555 (100)</td>
<td align="center">560 (100)</td>
</tr>
<tr>
<td class="Rrule" align="left">Treatment Failures</td>
<td class="Rrule" align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td class="Rrule" align="left">  Total VTE<a name="footnote-reference-21" href="#footnote-21" class="Sup">*</a> (%)</td>
<td class="Botrule Rrule" align="center">56 (10.1)<br>(95% CI<a name="footnote-reference-22" href="#footnote-22" class="Sup">†</a>: 8 to 13)</td>
<td class="Botrule" align="center">63 (11.3)<br>(95% CI: 9 to 14)</td>
</tr>
<tr class="Last">
<td class="Rrule" align="left">  DVT Only (%)</td>
<td class="Rrule" align="center">54 (9.7)<br>(95% CI: 7 to 12)</td>
<td align="center">61 (10.9)<br>(95% CI: 8 to 13)</td>
</tr>
</tbody>
</table>
<p>In a second double-blind, parallel group study, Lovenox 40 mg SC once a day was compared to heparin 5000 U every 8 hours SC in patients undergoing colorectal surgery (one-third with cancer). A total of 1347 patients were randomized in the study and all patients were treated. Patients ranged in age from 18 to 92 years (mean age 50.1 years) with 54.2% men and 45.8% women. Treatment was initiated approximately 2 hours prior to surgery and continued for approximately 7 to 10 days after surgery. The efficacy data are provided below [see<a href="#table15"> Table 15</a>].</p>
<a name="table15"></a><table width="100%">
<caption><span>Table 15 Efficacy of Lovenox in the Prophylaxis of <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">Deep Vein Thrombosis</span> Following Colorectal Surgery</span></caption>
<col align="left" valign="top" width="33%">
<col align="center" valign="top" width="34%">
<col align="center" valign="top" width="33%">
<thead>
<tr class="Botrule First">
<th class="Rrule" align="left" rowspan="2" valign="bottom">Indication</th>
<th align="center" colspan="2">Dosing Regimen</th>
</tr>
<tr class="Last">
<th class="Rrule" align="center">
<span class="Underline">Lovenox</span><br>40 mg q.d. SC<br>n (%)</th>
<th align="center">
<span class="Underline">Heparin</span><br>5000 U q8h SC<br>n (%)</th>
</tr>
</thead>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-23" href="#footnote-reference-23">*</a></dt>
<dd>VTE = Venous <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">thromboembolic events</span> which included DVT, PE, and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> considered to be thromboembolic in origin</dd>
<dt><a name="footnote-24" href="#footnote-reference-24">†</a></dt>
<dd>CI = Confidence Interval</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Rrule" align="left">All Treated Colorectal Surgery Patients</td>
<td class="Rrule" align="center">673 (100)</td>
<td align="center">674 (100)</td>
</tr>
<tr>
<td class="Rrule" align="left">Treatment Failures</td>
<td class="Rrule" align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td class="Rrule" align="left">  Total VTE<a name="footnote-reference-23" href="#footnote-23" class="Sup">*</a> (%)</td>
<td class="Botrule Rrule" align="center">48 (7.1)<br>(95% CI<a name="footnote-reference-24" href="#footnote-24" class="Sup">†</a>: 5 to 9)</td>
<td class="Botrule" align="center">45 (6.7)<br>(95% CI: 5 to 9)</td>
</tr>
<tr class="Last">
<td class="Rrule" align="left">  DVT Only (%)</td>
<td class="Rrule" align="center">47 (7.0)<br>(95% CI: 5 to 9)</td>
<td align="center">44 (6.5)<br>(95% CI: 5 to 8)</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S14.2"></a><a name="section-13.2"></a><p></p>
<h2>14.2 Prophylaxis of <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">Deep Vein Thrombosis</span> Following Hip or Knee Replacement Surgery</h2>
<p class="First">Lovenox has been shown to reduce the risk of post-operative <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">deep vein thrombosis</span> (DVT) following hip or knee replacement surgery.</p>
<p>In a double-blind study, Lovenox 30 mg every 12 hours SC was compared to placebo in patients with hip replacement. A total of 100 patients were randomized in the study and all patients were treated. Patients ranged in age from 41 to 84 years (mean age 67.1 years) with 45% men and 55% women. After hemostasis was established, treatment was initiated 12 to 24 hours after surgery and was continued for 10 to 14 days after surgery. The efficacy data are provided below [see<a href="#table16"> Table 16</a>].</p>
<a name="table16"></a><table width="100%">
<caption><span>Table 16 Efficacy of Lovenox in the Prophylaxis of <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">Deep Vein Thrombosis</span> Following Hip Replacement Surgery</span></caption>
<col align="left" valign="top" width="40%">
<col align="center" valign="top" width="30%">
<col align="center" valign="top" width="30%">
<thead>
<tr class="Botrule First">
<th class="Rrule" align="left" rowspan="2" valign="bottom">Indication</th>
<th align="center" colspan="2">Dosing Regimen</th>
</tr>
<tr class="Last">
<th class="Rrule" align="center">
<span class="Underline">Lovenox</span><br>30 mg q12h SC<br>n (%)</th>
<th align="center">
<span class="Underline">Placebo</span><br>q12h SC<br>n (%)</th>
</tr>
</thead>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-25" href="#footnote-reference-25">*</a></dt>
<dd>p value versus placebo = 0.0002</dd>
<dt><a name="footnote-26" href="#footnote-reference-26">†</a></dt>
<dd>p value versus placebo = 0.0134</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Rrule" align="left">All Treated Hip Replacement Patients</td>
<td class="Rrule" align="center">50 (100)</td>
<td align="center">50 (100)</td>
</tr>
<tr>
<td class="Rrule" align="left">Treatment Failures</td>
<td class="Rrule" align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td class="Rrule" align="left">  Total DVT (%)</td>
<td class="Botrule Rrule" align="center">5 (10)<a name="footnote-reference-25" href="#footnote-25" class="Sup">*</a>
</td>
<td class="Botrule" align="center">23 (46)</td>
</tr>
<tr class="Last">
<td class="Rrule" align="left">  Proximal DVT (%)</td>
<td class="Rrule" align="center">1 (2)<a name="footnote-reference-26" href="#footnote-26" class="Sup">†</a>
</td>
<td align="center">11 (22)</td>
</tr>
</tbody>
</table>
<p>A double-blind, multicenter study compared three dosing regimens of Lovenox in patients with hip replacement. A total of 572 patients were randomized in the study and 568 patients were treated. Patients ranged in age from 31 to 88 years (mean age 64.7 years) with 63% men and 37% women. Patients were 93% Caucasian, 6% Black, &lt;1% Asian, and 1% others. Treatment was initiated within two days after surgery and was continued for 7 to 11 days after surgery. The efficacy data are provided below [see<a href="#table17"> Table 17</a>].</p>
<a name="table17"></a><table width="100%">
<caption><span>Table 17 Efficacy of Lovenox in the Prophylaxis of <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">Deep Vein Thrombosis</span> Following Hip Replacement Surgery</span></caption>
<col align="left" valign="top" width="40%">
<col align="center" valign="top" width="20%">
<col align="center" valign="top" width="20%">
<col align="center" valign="top" width="20%">
<thead>
<tr class="Botrule First">
<th class="Rrule" align="left" rowspan="2" valign="bottom">Indication</th>
<th align="center" colspan="3">Dosing Regimen</th>
</tr>
<tr class="Last">
<th class="Rrule" align="center">10 mg q.d. SC<br>n (%)</th>
<th class="Rrule" align="center">30 mg q12h SC<br>n (%)</th>
<th align="center">40 mg q.d. SC<br>n (%)</th>
</tr>
</thead>
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-27" href="#footnote-reference-27">*</a></dt>
<dd>p value versus Lovenox 10 mg once a day = 0.0008</dd>
<dt><a name="footnote-28" href="#footnote-reference-28">†</a></dt>
<dd>p value versus Lovenox 10 mg once a day = 0.0168</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Rrule" align="left">All Treated Hip Replacement Patients</td>
<td class="Rrule" align="center">161 (100)</td>
<td class="Rrule" align="center">208 (100)</td>
<td align="center">199 (100)</td>
</tr>
<tr>
<td class="Rrule" align="left">Treatment Failures</td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td class="Rrule" align="left">  Total DVT (%)</td>
<td class="Botrule Rrule" align="center">40 (25)</td>
<td class="Botrule Rrule" align="center">22 (11)<a name="footnote-reference-27" href="#footnote-27" class="Sup">*</a>
</td>
<td class="Botrule" align="center">27 (14)</td>
</tr>
<tr class="Last">
<td class="Rrule" align="left">  Proximal DVT (%)</td>
<td class="Rrule" align="center">17 (11)</td>
<td class="Rrule" align="center">8 (4)<a name="footnote-reference-28" href="#footnote-28" class="Sup">†</a>
</td>
<td align="center">9 (5)</td>
</tr>
</tbody>
</table>
<p>There was no significant difference between the 30 mg every 12 hours and 40 mg once a day regimens. In a double-blind study, Lovenox 30 mg every 12 hours SC was compared to placebo in patients undergoing knee replacement surgery. A total of 132 patients were randomized in the study and 131 patients were treated<span class="Italics">, </span>of which 99 had total knee replacement and 32 had either unicompartmental knee replacement or tibial osteotomy. The 99 patients with total knee replacement ranged in age from 42 to 85 years (mean age 70.2 years) with 36.4% men and 63.6% women. After hemostasis was established, treatment was initiated 12 to 24 hours after surgery and was continued up to 15 days after surgery. The incidence of proximal and total DVT after surgery was significantly lower for Lovenox compared to placebo. The efficacy data are provided below [see<a href="#table18"> Table 18</a>].</p>
<a name="table18"></a><table width="100%">
<caption><span>Table 18 Efficacy of Lovenox in the Prophylaxis of <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">Deep Vein Thrombosis</span> Following Total Knee Replacement Surgery</span></caption>
<col align="left" valign="top" width="33%">
<col align="center" valign="top" width="34%">
<col align="center" valign="top" width="33%">
<thead>
<tr class="Botrule First">
<th class="Rrule" align="left" rowspan="2" valign="bottom">Indication</th>
<th align="center" colspan="2">Dosing Regimen</th>
</tr>
<tr class="Last">
<th class="Rrule" align="center">
<span class="Underline">Lovenox</span><br>30 mg q12h SC<br>n (%)</th>
<th align="center">
<span class="Underline">Placebo</span><br>q12h SC<br>n (%)</th>
</tr>
</thead>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-29" href="#footnote-reference-29">*</a></dt>
<dd>p value versus placebo = 0.0001</dd>
<dt><a name="footnote-30" href="#footnote-reference-30">†</a></dt>
<dd>CI = Confidence Interval</dd>
<dt><a name="footnote-31" href="#footnote-reference-31">‡</a></dt>
<dd>p value versus placebo = 0.013</dd>
<dt><a name="footnote-32" href="#footnote-reference-32">§</a></dt>
<dd>CL = Confidence Limit</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Rrule" align="left">All Treated Total Knee Replacement Patients</td>
<td class="Rrule" align="center">47 (100)</td>
<td align="center">52 (100)</td>
</tr>
<tr>
<td class="Rrule" align="left">Treatment Failures</td>
<td class="Rrule" align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td class="Rrule" align="left">  Total DVT (%)</td>
<td class="Botrule Rrule" align="center">5 (11)<a name="footnote-reference-29" href="#footnote-29" class="Sup">*</a><br>(95% CI<a name="footnote-reference-30" href="#footnote-30" class="Sup">†</a>: 1 to 21)</td>
<td class="Botrule" align="center">32 (62)<br>(95% CI: 47 to 76)</td>
</tr>
<tr class="Last">
<td class="Rrule" align="left">  Proximal DVT (%)</td>
<td class="Rrule" align="center">0 (0)<a name="footnote-reference-31" href="#footnote-31" class="Sup">‡</a><br>(95% Upper CL<a name="footnote-reference-32" href="#footnote-32" class="Sup">§</a>: 5)</td>
<td align="center">7 (13)<br>(95% CI: 3 to 24)</td>
</tr>
</tbody>
</table>
<p>Additionally, in an open-label, parallel group, randomized clinical study, Lovenox 30 mg every 12 hours SC in patients undergoing elective knee replacement surgery was compared to heparin 5000 U every 8 hours SC. A total of 453 patients were randomized in the study and all were treated. Patients ranged in age from 38 to 90 years (mean age 68.5 years) with 43.7% men and 56.3% women. Patients were 92.5% Caucasian, 5.3% Black, and 0.6% others. Treatment was initiated after surgery and continued up to 14 days. The incidence of <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">deep vein thrombosis</span> was significantly lower for Lovenox compared to heparin.</p>
<p>Extended Prophylaxis of <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">Deep Vein Thrombosis</span> Following Hip Replacement Surgery: In a study of extended prophylaxis for patients undergoing hip replacement surgery, patients were treated, while hospitalized, with Lovenox 40 mg SC, initiated up to 12 hours prior to surgery for the prophylaxis of post-operative DVT. At the end of the peri-operative period, all patients underwent bilateral venography. In a double-blind design, those patients with no venous thromboembolic disease were randomized to a post-discharge regimen of either Lovenox 40 mg (n = 90) once a day SC or to placebo (n = 89) for 3 weeks. A total of 179 patients were randomized in the double-blind phase of the study and all patients were treated.  Patients ranged in age from 47 to 87 years (mean age 69.4 years) with 57% men and 43% women. In this population of patients, the incidence of DVT during extended prophylaxis was significantly lower for Lovenox compared to placebo. The efficacy data are provided below [see<a href="#table19"> Table 19</a>].</p>
<a name="table19"></a><table width="100%">
<caption><span>Table 19 Efficacy of Lovenox in the Extended Prophylaxis of <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">Deep Vein Thrombosis</span> Following Hip Replacement Surgery</span></caption>
<col align="left" valign="top" width="50%">
<col align="center" valign="top" width="25%">
<col align="center" valign="top" width="25%">
<thead>
<tr class="Botrule First">
<th class="Rrule" align="left" rowspan="2" valign="bottom">Indication (Post-Discharge)</th>
<th align="center" colspan="2">Post-Discharge Dosing Regimen</th>
</tr>
<tr class="Last">
<th class="Rrule" align="center">
<span class="Underline">Lovenox</span><br>40 mg q.d. SC<br>n (%)</th>
<th align="center">
<span class="Underline">Placebo</span><br>q.d. SC<br>n (%)</th>
</tr>
</thead>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-33" href="#footnote-reference-33">*</a></dt>
<dd>p value versus placebo = 0.008 </dd>
<dt><a name="footnote-34" href="#footnote-reference-34">†</a></dt>
<dd>CI= Confidence Interval</dd>
<dt><a name="footnote-35" href="#footnote-reference-35">‡</a></dt>
<dd>p value versus placebo = 0.537</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Rrule" align="left">All Treated Extended Prophylaxis Patients</td>
<td class="Rrule" align="center">90 (100)</td>
<td align="center">89 (100)</td>
</tr>
<tr>
<td class="Rrule" align="left">Treatment Failures</td>
<td class="Rrule" align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td class="Rrule" align="left">  Total DVT (%)</td>
<td class="Botrule Rrule" align="center">6 (7)<a name="footnote-reference-33" href="#footnote-33" class="Sup">*</a><br>(95% CI<a name="footnote-reference-34" href="#footnote-34" class="Sup">†</a> : 3 to 14)</td>
<td class="Botrule" align="center">18 (20)<br>(95% CI: 12 to 30)</td>
</tr>
<tr class="Last">
<td class="Rrule" align="left">  Proximal DVT (%)</td>
<td class="Rrule" align="center">5 (6)<a name="footnote-reference-35" href="#footnote-35" class="Sup">‡</a><br>(95% CI: 2 to 13)</td>
<td align="center">7 (8)<br>(95% CI: 3 to 16)</td>
</tr>
</tbody>
</table>
<p>In a second study, patients undergoing hip replacement surgery were treated, while hospitalized, with Lovenox 40 mg SC, initiated up to 12 hours prior to surgery. All patients were examined for clinical signs and symptoms of venous thromboembolic (VTE) disease. In a double-blind design, patients without clinical signs and symptoms of VTE disease were randomized to a post-discharge regimen of either Lovenox 40 mg (n = 131) once a day SC or to placebo (n = 131) for 3 weeks. A total of 262 patients were randomized in the study double-blind phase and all patients were treated. Patients ranged in age from 44 to 87 years (mean age 68.5 years) with 43.1% men and 56.9% women. Similar to the first study the incidence of DVT during extended prophylaxis was significantly lower for Lovenox compared to placebo, with a statistically significant difference in both total DVT (Lovenox 21 [16%] versus placebo 45 [34%]; p = 0.001) and proximal DVT (Lovenox 8 [6%] versus placebo 28 [21%]; p = &lt;0.001).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S14.3"></a><a name="section-13.3"></a><p></p>
<h2>14.3 Prophylaxis of <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">Deep Vein Thrombosis</span> in Medical Patients with Severely Restricted Mobility During Acute Illness </h2>
<p class="First">In a double blind multicenter, parallel group study, Lovenox 20 mg or 40 mg once a day SC was compared to placebo in the prophylaxis of <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">deep vein thrombosis</span> (DVT) in medical patients with severely restricted mobility during acute illness (defined as walking distance of &lt;10 meters for ≤3 days). This study included patients with <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> (NYHA Class III or IV); <span class="product-label-link" type="condition" conceptid="319049" conceptname="Acute respiratory failure">acute respiratory failure</span> or complicated chronic <span class="product-label-link" type="condition" conceptid="318459" conceptname="Respiratory insufficiency">respiratory insufficiency</span> (not requiring ventilatory support): acute <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> (excluding <span class="product-label-link" type="condition" conceptid="196236" conceptname="Septic shock">septic shock</span>); or acute rheumatic disorder [acute lumbar or sciatic <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, vertebral compression (due to <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span> or tumor), acute arthritic episodes of the lower extremities]. A total of 1102 patients were enrolled in the study, and 1073 patients were treated. Patients ranged in age from 40 to 97 years (mean age 73 years) with equal proportions of men and women. Treatment continued for a maximum of 14 days (median duration 7 days). When given at a dose of 40 mg once a day SC, Lovenox significantly reduced the incidence of DVT as compared to placebo. The efficacy data are provided below [see<a href="#table20"> Table 20</a>].</p>
<a name="table20"></a><table width="100%">
<caption><span>Table 20 Efficacy of Lovenox in the Prophylaxis of <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">Deep Vein Thrombosis</span> in Medical Patients with Severely Restricted Mobility During Acute Illness </span></caption>
<col align="left" valign="top" width="25%">
<col align="center" valign="top" width="25%">
<col align="center" valign="top" width="25%">
<col align="center" valign="top" width="25%">
<thead>
<tr class="Botrule First">
<th class="Rrule" align="left" rowspan="2" valign="bottom">Indication</th>
<th align="center" colspan="3">Dosing Regimen</th>
</tr>
<tr class="Last">
<th class="Rrule" align="center">
<span class="Underline">Lovenox</span><br>20 mg q.d. SC<br>n (%)</th>
<th class="Rrule" align="center">
<span class="Underline">Lovenox</span><br>40 mg q.d. SC<br>n (%)</th>
<th align="center">
<span class="Underline">Placebo</span><br> <br>n (%)</th>
</tr>
</thead>
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-36" href="#footnote-reference-36">*</a></dt>
<dd>Treatment failures during therapy, between Days 1 and 14</dd>
<dt><a name="footnote-37" href="#footnote-reference-37">†</a></dt>
<dd>VTE = Venous <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">thromboembolic events</span> which included DVT, PE, and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> considered to be thromboembolic in origin</dd>
<dt><a name="footnote-38" href="#footnote-reference-38">‡</a></dt>
<dd>CI = Confidence Interval </dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Rrule" align="left">All Treated Medical Patients During Acute Illness</td>
<td class="Rrule" align="center">351 (100)</td>
<td class="Rrule" align="center">360 (100)</td>
<td align="center">362 (100)</td>
</tr>
<tr>
<td class="Rrule" align="left">Treatment Failure<a name="footnote-reference-36" href="#footnote-36" class="Sup">*</a>
</td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td class="Rrule" align="left">Total VTE<a name="footnote-reference-37" href="#footnote-37" class="Sup">†</a> (%)</td>
<td class="Botrule Rrule" align="center">43 (12.3)</td>
<td class="Botrule Rrule" align="center">16 (4.4)</td>
<td class="Botrule" align="center">43 (11.9)</td>
</tr>
<tr>
<td class="Rrule" align="right">Total DVT (%)</td>
<td class="Botrule Rrule" align="center">43 (12.3)<br>(95% CI<a name="footnote-reference-38" href="#footnote-38" class="Sup">‡</a> 8.8 to 15.7)</td>
<td class="Botrule Rrule" align="center">16 (4.4)<br>(95% CI<a href="#footnote-38" class="Sup">‡</a> 2.3 to 6.6)</td>
<td class="Botrule" align="center">41 (11.3)<br>(95% CI<a href="#footnote-38" class="Sup">‡</a> 8.1 to 14.6)</td>
</tr>
<tr class="Last">
<td class="Rrule" align="right">Proximal DVT (%)</td>
<td class="Rrule" align="center">13 (3.7)</td>
<td class="Rrule" align="center">5 (1.4)</td>
<td align="center">14 (3.9)</td>
</tr>
</tbody>
</table>
<p>At approximately 3 months following enrollment, the incidence of <span class="product-label-link" type="condition" conceptid="318775" conceptname="Venous embolism">venous thromboembolism</span> remained significantly lower in the Lovenox 40 mg treatment group versus the placebo treatment group.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S14.4"></a><a name="section-13.4"></a><p></p>
<h2>14.4 Treatment of <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">Deep Vein Thrombosis</span> with or without <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">Pulmonary Embolism</span> </h2>
<p class="First">In a multicenter, parallel group study, 900 patients with acute lower extremity <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">deep vein thrombosis</span> (DVT) with or without <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span> (PE) were randomized to an inpatient (hospital) treatment of either (i) Lovenox 1.5 mg/kg once a day SC, (ii) Lovenox 1 mg/kg every 12 hours SC, or (iii) heparin IV bolus (5000 IU) followed by a continuous infusion (administered to achieve an aPTT of 55 to 85 seconds). A total of 900 patients were randomized in the study and all patients were treated. Patients ranged in age from 18 to 92 years (mean age 60.7 years) with 54.7% men and 45.3% women. All patients also received warfarin sodium (dose adjusted according to PT to achieve an International Normalization Ratio [INR] of 2.0 to 3.0), commencing within 72 hours of initiation of Lovenox or standard heparin therapy, and continuing for 90 days. Lovenox or standard heparin therapy was administered for a minimum of 5 days and until the targeted warfarin sodium INR was achieved. Both Lovenox regimens were equivalent to standard heparin therapy in reducing the risk of recurrent <span class="product-label-link" type="condition" conceptid="318775" conceptname="Venous embolism">venous thromboembolism</span> (DVT and/or PE). The efficacy data are provided below [see<a href="#table21"> Table 21</a>].</p>
<a name="table21"></a><table width="100%">
<caption><span>Table 21 Efficacy of Lovenox in Treatment of <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">Deep Vein Thrombosis</span> with or without <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">Pulmonary Embolism</span></span></caption>
<col align="left" valign="top" width="25%">
<col align="center" valign="top" width="25%">
<col align="center" valign="top" width="25%">
<col align="center" valign="top" width="25%">
<thead>
<tr class="Botrule First">
<th class="Rrule" align="left" rowspan="2" valign="bottom">Indication</th>
<th align="center" colspan="3">Dosing Regimen<a name="footnote-reference-39" href="#footnote-39" class="Sup">*</a>
</th>
</tr>
<tr class="Last">
<th class="Rrule" align="center">
<span class="Underline">Lovenox</span><br>1.5 mg/kg q.d. SC<br> <br>n (%)</th>
<th class="Rrule" align="center">
<span class="Underline">Lovenox</span><br>1 mg/kg q12h SC<br> <br>n (%)</th>
<th align="center">
<span class="Underline">Heparin</span><br>aPTT Adjusted IV Therapy<br>n (%)</th>
</tr>
</thead>
<tfoot><tr><td colspan="4" align="left"><dl class="Footnote">
<dt><a name="footnote-39" href="#footnote-reference-39">*</a></dt>
<dd>All patients were also treated with warfarin sodium commencing within 72 hours of Lovenox or standard heparin therapy.</dd>
<dt><a name="footnote-40" href="#footnote-reference-40">†</a></dt>
<dd>VTE = venous <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">thromboembolic event</span> (DVT and/or PE)</dd>
<dt><a name="footnote-41" href="#footnote-reference-41">‡</a></dt>
<dd>The 95% Confidence Intervals for the treatment differences for total VTE were:<br>Lovenox once a day versus heparin (-3.0 to 3.5)<br>Lovenox every 12 hours versus heparin (-4.2 to 1.7).</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Rrule" align="left">All Treated DVT Patients with or without PE</td>
<td class="Rrule" align="center">298 (100)</td>
<td class="Rrule" align="center">312 (100)</td>
<td align="center">290 (100)</td>
</tr>
<tr>
<td class="Rrule" align="left">Patient Outcome</td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td class="Rrule" align="left">Total VTE<a name="footnote-reference-40" href="#footnote-40" class="Sup">†</a> (%)</td>
<td class="Botrule Rrule" align="center">13 (4.4)<a name="footnote-reference-41" href="#footnote-41" class="Sup">‡</a>
</td>
<td class="Botrule Rrule" align="center">9 (2.9) <a href="#footnote-41" class="Sup">‡</a>
</td>
<td class="Botrule" align="center">12 (4.1)</td>
</tr>
<tr>
<td class="Rrule" align="right">DVT Only (%)</td>
<td class="Botrule Rrule" align="center">11 (3.7)</td>
<td class="Botrule Rrule" align="center">7 (2.2)</td>
<td class="Botrule" align="center">8 (2.8)</td>
</tr>
<tr>
<td class="Rrule" align="right">Proximal DVT (%)</td>
<td class="Botrule Rrule" align="center">9 (3.0)</td>
<td class="Botrule Rrule" align="center">6 (1.9)</td>
<td class="Botrule" align="center">7 (2.4)</td>
</tr>
<tr class="Last">
<td class="Rrule" align="right">PE (%)</td>
<td class="Rrule" align="center">2 (0.7)</td>
<td class="Rrule" align="center">2 (0.6)</td>
<td align="center">4 (1.4)</td>
</tr>
</tbody>
</table>
<p>Similarly, in a multicenter, open-label, parallel group study, patients with acute proximal DVT were randomized to Lovenox or heparin. Patients who could not receive outpatient therapy were excluded from entering the study. Outpatient exclusion criteria included the following:  inability to receive outpatient heparin therapy because of associated co-morbid conditions or potential for non-compliance and inability to attend follow-up visits as an outpatient because of geographic inaccessibility. Eligible patients could be treated in the hospital, but ONLY Lovenox patients were permitted to go home on therapy (72%). A total of 501 patients were randomized in the study and all patients were treated. Patients ranged in age from 19 to 96 years (mean age 57.8 years) with 60.5% men and 39.5% women. Patients were randomized to either Lovenox 1 mg/kg every 12 hours SC or heparin IV bolus (5000 IU) followed by a continuous infusion administered to achieve an aPTT of 60 to 85 seconds (in-patient treatment). All patients also received warfarin sodium as described in the previous study. Lovenox or standard heparin therapy was administered for a minimum of 5 days. Lovenox was equivalent to standard heparin therapy in reducing the risk of recurrent <span class="product-label-link" type="condition" conceptid="318775" conceptname="Venous embolism">venous thromboembolism</span>. The efficacy data are provided below [see<a href="#table22"> Table 22</a>].</p>
<a name="table22"></a><table width="100%">
<caption><span>Table 22 Efficacy of Lovenox in Treatment of <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">Deep Vein Thrombosis</span></span></caption>
<col align="left" valign="top" width="50%">
<col align="center" valign="top" width="25%">
<col align="center" valign="top" width="25%">
<thead>
<tr class="Botrule First">
<th class="Rrule" align="left" rowspan="2" valign="bottom">Indication</th>
<th align="center" colspan="2">Dosing Regimen<a name="footnote-reference-42" href="#footnote-42" class="Sup">*</a>
</th>
</tr>
<tr class="Last">
<th class="Rrule" align="center">
<span class="Underline">Lovenox</span><br>1 mg/kg q12h SC<br> <br>n (%)</th>
<th align="center">
<span class="Underline">Heparin</span><br>aPTT Adjusted IV Therapy<br>n (%)</th>
</tr>
</thead>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-42" href="#footnote-reference-42">*</a></dt>
<dd>All patients were also treated with warfarin sodium commencing on the evening of the second day of Lovenox or standard heparin therapy.</dd>
<dt><a name="footnote-43" href="#footnote-reference-43">†</a></dt>
<dd>VTE = venous <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">thromboembolic event</span> (<span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">deep vein thrombosis</span> [DVT] and/or <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span> [PE]).</dd>
<dt><a name="footnote-44" href="#footnote-reference-44">‡</a></dt>
<dd>The 95% Confidence Intervals for the treatment difference for total VTE was: Lovenox versus heparin (- 5.6 to 2.7).</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Rrule" align="left">All Treated DVT Patients</td>
<td class="Rrule" align="center">247 (100)</td>
<td align="center">254 (100)</td>
</tr>
<tr>
<td class="Rrule" align="left">Patient Outcome</td>
<td class="Rrule" align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td class="Rrule" align="left">Total VTE<a name="footnote-reference-43" href="#footnote-43" class="Sup">†</a> (%)</td>
<td class="Botrule Rrule" align="center">13 (5.3) <a name="footnote-reference-44" href="#footnote-44" class="Sup">‡</a>
</td>
<td class="Botrule" align="center">17 (6.7)</td>
</tr>
<tr>
<td class="Rrule" align="right">DVT Only (%)</td>
<td class="Botrule Rrule" align="center">11 (4.5)</td>
<td class="Botrule" align="center">14 (5.5)</td>
</tr>
<tr>
<td class="Rrule" align="right">Proximal DVT (%)</td>
<td class="Botrule Rrule" align="center">10 (4.0)</td>
<td class="Botrule" align="center">12 (4.7)</td>
</tr>
<tr class="Last">
<td class="Rrule" align="right">PE (%)</td>
<td class="Rrule" align="center">2 (0.8)</td>
<td align="center">3 (1.2)</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S14.5"></a><a name="section-13.5"></a><p></p>
<h2>14.5 Prophylaxis of Ischemic Complications in <span class="product-label-link" type="condition" conceptid="315296" conceptname="Preinfarction syndrome">Unstable Angina</span> and Non-Q-Wave <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Myocardial Infarction</span> </h2>
<p class="First">In a multicenter, double-blind, parallel group study, patients who recently experienced <span class="product-label-link" type="condition" conceptid="315296" conceptname="Preinfarction syndrome">unstable angina</span> or non-Q-wave <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> were randomized to either Lovenox 1 mg/kg every 12 hours SC or heparin IV bolus (5000 U) followed by a continuous infusion (adjusted to achieve an aPTT of 55 to 85 seconds). A total of 3171 patients were enrolled in the study, and 3107 patients were treated. Patients ranged in age from 25–94 years (median age 64 years), with 33.4% of patients female and 66.6% male. Race was distributed as follows: 89.8% Caucasian, 4.8% Black, 2.0% Asian, and 3.5% other. <span class="Bold"><span class="Underline">All</span></span> patients were also treated with aspirin 100 to 325 mg per day. Treatment was initiated within 24 hours of the event and continued until clinical stabilization, revascularization procedures, or hospital discharge, with a maximal duration of 8 days of therapy. The combined incidence of the triple endpoint of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, or recurrent angina was lower for Lovenox compared with heparin therapy at 14 days after initiation of treatment. The lower incidence of the triple endpoint was sustained up to 30 days after initiation of treatment. These results were observed in an analysis of both all-randomized and all-treated patients. The efficacy data are provided below [see<a href="#table23"> Table 23</a>].</p>
<a name="table23"></a><table width="100%">
<caption><span>Table 23 Efficacy of Lovenox in the Prophylaxis of Ischemic Complications in <span class="product-label-link" type="condition" conceptid="315296" conceptname="Preinfarction syndrome">Unstable Angina</span> and Non-Q-Wave <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Myocardial Infarction</span> (Combined Endpoint of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span>, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Myocardial Infarction</span>, or Recurrent Angina)</span></caption>
<col align="left" valign="top" width="20%">
<col align="center" valign="top" width="20%">
<col align="center" valign="top" width="20%">
<col align="center" valign="top" width="20%">
<col align="center" valign="top" width="20%">
<thead>
<tr class="First">
<th class="Rrule" align="left" rowspan="2" valign="bottom">Indication</th>
<th class="Botrule Rrule" align="center" colspan="2">Dosing Regimen<a name="footnote-reference-45" href="#footnote-45" class="Sup">*</a>
</th>
<th class="Rrule" align="center"></th>
<th align="center"></th>
</tr>
<tr class="Last">
<th class="Rrule" align="center">
<span class="Underline">Lovenox</span><br>1mg/kg q12h SC<br> <br>n (%)</th>
<th class="Rrule" align="center">
<span class="Underline">Heparin</span><br>aPTT Adjusted IV Therapy<br>n (%)</th>
<th class="Rrule" align="center">
<span class="Underline">Reduction</span><br>(%)</th>
<th align="center"><span class="Underline">p Value</span></th>
</tr>
</thead>
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-45" href="#footnote-reference-45">*</a></dt>
<dd>All patients were also treated with aspirin 100 to 325 mg per day.</dd>
<dt><a name="footnote-46" href="#footnote-reference-46">†</a></dt>
<dd>Evaluation timepoints are after initiation of treatment. Therapy continued for up to 8 days (median duration of 2.6 days).</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Rrule" align="left">All Treated <span class="product-label-link" type="condition" conceptid="315296" conceptname="Preinfarction syndrome">Unstable Angina</span> and Non-Q-Wave MI Patients</td>
<td class="Rrule" align="center">1578 (100)</td>
<td class="Rrule" align="center">1529 (100)</td>
<td class="Rrule" align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td class="Rrule" align="left">Timepoint<a name="footnote-reference-46" href="#footnote-46" class="Sup">†</a>
</td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td class="Rrule" align="left">  48 Hours</td>
<td class="Botrule Rrule" align="center">96 (6.1)</td>
<td class="Botrule Rrule" align="center">112 (7.3)</td>
<td class="Botrule Rrule" align="center">1.2</td>
<td class="Botrule" align="center">0.120</td>
</tr>
<tr>
<td class="Rrule" align="left">  14 Days</td>
<td class="Botrule Rrule" align="center">261 (16.5)</td>
<td class="Botrule Rrule" align="center">303 (19.8)</td>
<td class="Botrule Rrule" align="center">3.3</td>
<td class="Botrule" align="center">0.017</td>
</tr>
<tr class="Last">
<td class="Rrule" align="left">  30 Days</td>
<td class="Rrule" align="center">313 (19.8)</td>
<td class="Rrule" align="center">358 (23.4)</td>
<td class="Rrule" align="center">3.6</td>
<td align="center">0.014</td>
</tr>
</tbody>
</table>
<p>The combined incidence of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> or <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> at all time points was lower for Lovenox compared to standard heparin therapy, but did not achieve statistical significance. The efficacy data are provided below [see<a href="#table24"> Table 24</a>].</p>
<a name="table24"></a><table width="100%">
<caption><span>Table 24 Efficacy of Lovenox in the Prophylaxis of Ischemic Complications in <span class="product-label-link" type="condition" conceptid="315296" conceptname="Preinfarction syndrome">Unstable Angina</span> and Non-Q-Wave <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Myocardial Infarction</span> (Combined Endpoint of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span> or <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Myocardial Infarction</span>)</span></caption>
<col align="left" valign="top" width="20%">
<col align="center" valign="top" width="20%">
<col align="center" valign="top" width="20%">
<col align="center" valign="top" width="20%">
<col align="center" valign="top" width="20%">
<thead>
<tr class="First">
<th class="Rrule" align="left" rowspan="2" valign="bottom">Indication</th>
<th class="Botrule Rrule" align="center" colspan="2">Dosing Regimen<a name="footnote-reference-47" href="#footnote-47" class="Sup">*</a>
</th>
<th class="Rrule" align="center"></th>
<th align="center"></th>
</tr>
<tr class="Last">
<th class="Rrule" align="center">
<span class="Underline">Lovenox</span><br>1 mg/kg q12h SC<br> <br>n (%)</th>
<th class="Rrule" align="center">
<span class="Underline">Heparin</span><br>aPTT Adjusted  IV Therapy<br>n (%)</th>
<th class="Rrule" align="center">
<span class="Underline">Reduction</span><br>(%)</th>
<th align="center"><span class="Underline">p Value</span></th>
</tr>
</thead>
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-47" href="#footnote-reference-47">*</a></dt>
<dd>All patients were also treated with aspirin 100 to 325 mg per day.</dd>
<dt><a name="footnote-48" href="#footnote-reference-48">†</a></dt>
<dd>Evaluation timepoints are after initiation of treatment. Therapy continued for up to 8 days (median duration of 2.6 days).</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td class="Rrule" align="left">All Treated <span class="product-label-link" type="condition" conceptid="315296" conceptname="Preinfarction syndrome">Unstable Angina</span> and Non-Q-Wave MI Patients</td>
<td class="Rrule" align="center">1578 (100)</td>
<td class="Rrule" align="center">1529 (100)</td>
<td class="Rrule" align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td class="Rrule" align="left">Timepoint<a name="footnote-reference-48" href="#footnote-48" class="Sup">†</a>
</td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td class="Rrule" align="left">  48 Hours</td>
<td class="Botrule Rrule" align="center">16 (1.0)</td>
<td class="Botrule Rrule" align="center">20 (1.3)</td>
<td class="Botrule Rrule" align="center">0.3</td>
<td class="Botrule" align="center">0.126</td>
</tr>
<tr>
<td class="Rrule" align="left">  14 Days</td>
<td class="Botrule Rrule" align="center">76 (4.8)</td>
<td class="Botrule Rrule" align="center">93 (6.1)</td>
<td class="Botrule Rrule" align="center">1.3</td>
<td class="Botrule" align="center">0.115</td>
</tr>
<tr class="Last">
<td class="Rrule" align="left">  30 Days</td>
<td class="Rrule" align="center">96 (6.1)</td>
<td class="Rrule" align="center">118 (7.7)</td>
<td class="Rrule" align="center">1.6</td>
<td align="center">0.069</td>
</tr>
</tbody>
</table>
<p>In a survey one year following treatment, with information available for 92% of enrolled patients, the combined incidence of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, or recurrent angina remained lower for Lovenox versus heparin (32.0% vs 35.7%).</p>
<p>Urgent revascularization procedures were performed less frequently in the Lovenox group as compared to the heparin group, 6.3% compared to 8.2% at 30 days (p = 0.047).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S14.6"></a><a name="section-13.6"></a><p></p>
<h2>14.6 Treatment of Acute ST-Segment Elevation <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Myocardial Infarction</span></h2>
<p class="First">In a multicenter, double-blind, double-dummy, parallel group study, patients with acute ST-segment elevation <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> (<span class="product-label-link" type="condition" conceptid="312327" conceptname="Acute myocardial infarction">STEMI</span>) who were to be hospitalized within 6 hours of onset and were eligible to receive fibrinolytic therapy were randomized in a 1:1 ratio to receive either Lovenox or unfractionated heparin.</p>
<p>Study medication was initiated between 15 minutes before and 30 minutes after the initiation of fibrinolytic therapy. Unfractionated heparin was administered beginning with an IV bolus of 60 U/kg (maximum 4000 U) and followed with an infusion of 12 U/kg per hour (initial maximum 1000 U per hour) that was adjusted to maintain an aPTT of 1.5 to 2 times the control value. The IV infusion was to be given for at least 48 hours. The enoxaparin dosing strategy was adjusted according to the patient's age and renal function. For patients younger than 75 years of age, enoxaparin was given as a single 30 mg intravenous bolus plus a 1 mg/kg SC dose followed by an SC injection of 1 mg/kg every 12 hours. For patients at least 75 years of age, the IV bolus was not given and the SC dose was reduced to 0.75 mg/kg every 12 hours. For patients with severe <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span> (estimated creatinine clearance of less than 30 mL per minute), the dose was to be modified to 1 mg/kg every 24 hours. The SC injections of enoxaparin were given until hospital discharge or for a maximum of eight days (whichever came first). The mean treatment duration for enoxaparin was 6.6 days. The mean treatment duration of unfractionated heparin was 54 hours.</p>
<p>When percutaneous coronary intervention was performed during study medication period, patients received antithrombotic support with blinded study drug. For patients on enoxaparin, the PCI was to be performed on enoxaparin (no switch) using the regimen established in previous studies, <span class="Italics">i.e.</span> no additional dosing, if the last SC administration was less than 8 hours before balloon inflation, IV bolus of 0.3 mg/kg enoxaparin if the last SC administration was more than 8 hours before balloon inflation.</p>
<p>All patients were treated with aspirin for a minimum of 30 days. Eighty percent of patients received a fibrin-specific agent (19% tenecteplase, 5% reteplase and 55% alteplase) and 20% received streptokinase.</p>
<p>Among 20,479 patients in the ITT population, the mean age was 60 years, and 76% were male. Racial distribution was: 87% Caucasian, 9.8% Asian, 0.2% Black, and 2.8% other. Medical history included previous MI (13%), <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> (44%), <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> (15%) and angiographic evidence of CAD (5%). Concomitant medication included aspirin (95%), beta-blockers (86%), ACE inhibitors (78%), statins (70%) and clopidogrel (27%). The MI at entry was anterior in 43%, non-anterior in 56%, and both in 1%.</p>
<p>The primary efficacy end point was the composite of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> from any cause or myocardial re-<span class="product-label-link" type="condition" conceptid="4206471" conceptname="Infarct">infarction</span> in the first 30 days after randomization. Total follow-up was one year.</p>
<p>The rate of the primary efficacy end point (<span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> or myocardial re-<span class="product-label-link" type="condition" conceptid="4206471" conceptname="Infarct">infarction</span>) was 9.9% in the enoxaparin group, and 12.0% in the unfractionated heparin group, a 17% reduction in the relative risk, (P=0.000003) [see<a href="#table25"> Table 25</a>].</p>
<a name="table25"></a><table width="100%">
<caption><span>Table 25 Efficacy of Lovenox in the Treatment of Acute ST-Segment Elevation <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">Myocardial Infarction</span></span></caption>
<col align="left" valign="top" width="40%">
<col align="center" valign="top" width="12%">
<col align="center" valign="top" width="12%">
<col align="center" valign="top" width="24%">
<col align="center" valign="top" width="12%">
<thead><tr class="First Last">
<th align="left"></th>
<th align="center">Enoxaparin<br>(N=10,256)</th>
<th align="center">UFH<br>(N=10,223)</th>
<th align="center">Relative Risk<br>(95% CI)</th>
<th align="center">P Value</th>
</tr></thead>
<tfoot><tr class="First Last"><td align="left" colspan="5">Note: Urgent revascularization denotes episodes of recurrent <span class="product-label-link" type="condition" conceptid="4124683" conceptname="Silent myocardial ischemia">myocardial ischemia</span> (without <span class="product-label-link" type="condition" conceptid="4206471" conceptname="Infarct">infarction</span>) leading to the clinical decision to perform coronary revascularization during the same hospitalization. CI denotes confidence intervals.</td></tr></tfoot>
<tbody>
<tr class="Botrule First">
<td align="center">Outcome at 48 hours</td>
<td align="center">n (%)</td>
<td align="center">n (%)</td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span> or Myocardial Re-<span class="product-label-link" type="condition" conceptid="4206471" conceptname="Infarct">infarction</span> </td>
<td align="center">478 (4.7)</td>
<td align="center">531 (5.2)</td>
<td align="center">0.90 (0.80 to 1.01)</td>
<td align="center">0.08</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span></td>
<td align="center">383 (3.7)</td>
<td align="center">390 (3.8)</td>
<td align="center">0.98 (0.85 to 1.12)</td>
<td align="center">0.76</td>
</tr>
<tr>
<td align="left">  Myocardial Re-<span class="product-label-link" type="condition" conceptid="4206471" conceptname="Infarct">infarction</span></td>
<td align="center">102 (1.0)</td>
<td align="center">156 (1.5)</td>
<td align="center">0.65 (0.51 to 0.84)</td>
<td align="center">&lt;0.001</td>
</tr>
<tr>
<td align="left">Urgent Revascularization</td>
<td align="center">74 (0.7)</td>
<td align="center">96 (0.9)</td>
<td align="center">0.77 (0.57 to 1.04)</td>
<td align="center">0.09</td>
</tr>
<tr class="Botrule">
<td align="left"><span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span> or Myocardial Re-<span class="product-label-link" type="condition" conceptid="4206471" conceptname="Infarct">infarction</span> or Urgent Revascularization</td>
<td align="center">548 (5.3)</td>
<td align="center">622 (6.1)</td>
<td align="center">0.88 (0.79 to 0.98)</td>
<td align="center">0.02</td>
</tr>
<tr class="Botrule">
<td align="center">Outcome at 8 Days</td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span> or Myocardial Re-<span class="product-label-link" type="condition" conceptid="4206471" conceptname="Infarct">infarction</span></td>
<td align="center">740 (7.2)</td>
<td align="center">954 (9.3)</td>
<td align="center">0.77 (0.71 to 0.85)</td>
<td align="center">&lt;0.001</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span></td>
<td align="center">559 (5.5)</td>
<td align="center">605 (5.9)</td>
<td align="center">0.92 (0.82 to 1.03)</td>
<td align="center">0.15</td>
</tr>
<tr>
<td align="left">  Myocardial Re-<span class="product-label-link" type="condition" conceptid="4206471" conceptname="Infarct">infarction</span></td>
<td align="center">204 (2.0)</td>
<td align="center">379 (3.7)</td>
<td align="center">0.54 (0.45 to 0.63)</td>
<td align="center">&lt;0.001</td>
</tr>
<tr>
<td align="left">Urgent Revascularization</td>
<td align="center">145 (1.4)</td>
<td align="center">247 (2.4)</td>
<td align="center">0.59 (0.48 to 0.72)</td>
<td align="center">&lt;0.001</td>
</tr>
<tr class="Botrule">
<td align="left"><span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span> or Myocardial Re-<span class="product-label-link" type="condition" conceptid="4206471" conceptname="Infarct">infarction</span> or Urgent Revascularization</td>
<td align="center">874 (8.5)</td>
<td align="center">1181 (11.6)</td>
<td align="center">0.74 (0.68 to 0.80)</td>
<td align="center">&lt;0.001</td>
</tr>
<tr class="Botrule">
<td align="center"><span class="Bold">Outcome at 30 Days</span></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td align="left"><span class="Bold">Primary efficacy endpoint<br>(<span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span> or Myocardial Re-<span class="product-label-link" type="condition" conceptid="4206471" conceptname="Infarct">infarction</span>)</span></td>
<td align="center" valign="bottom"><span class="Bold">1017 (9.9)</span></td>
<td align="center" valign="bottom"><span class="Bold">1223 (12.0)</span></td>
<td align="center" valign="bottom"><span class="Bold">0.83 (0.77 to 0.90)</span></td>
<td align="center" valign="bottom"><span class="Bold">0.000003</span></td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span></td>
<td align="center">708 (6.9)</td>
<td align="center">765 (7.5)</td>
<td align="center">0.92 (0.84 to 1.02)</td>
<td align="center">0.11</td>
</tr>
<tr>
<td align="left">  Myocardial Re-<span class="product-label-link" type="condition" conceptid="4206471" conceptname="Infarct">infarction</span></td>
<td align="center">352 (3.4)</td>
<td align="center">508 (5.0)</td>
<td align="center">0.69 (0.60 to 0.79)</td>
<td align="center">&lt;0.001</td>
</tr>
<tr>
<td align="left">Urgent Revascularization</td>
<td align="center">213 (2.1)</td>
<td align="center">286 (2.8)</td>
<td align="center">0.74 (0.62 to 0.88)</td>
<td align="center">&lt;0.001</td>
</tr>
<tr class="Last">
<td align="left"><span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span> or Myocardial Re-<span class="product-label-link" type="condition" conceptid="4206471" conceptname="Infarct">infarction</span> or Urgent Revascularization</td>
<td align="center">1199 (11.7)</td>
<td align="center">1479 (14.5)</td>
<td align="center">0.81 (0.75 to 0.87)</td>
<td align="center">&lt;0.001</td>
</tr>
</tbody>
</table>
<p>The beneficial effect of enoxaparin on the primary end point was consistent across key subgroups including age, gender, infarct location, history of <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, history of prior <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, fibrinolytic agent administered, and time to treatment with study drug (see<a href="#fig1"> Figure 1</a>); however, it is necessary to interpret such subgroup analyses with caution.</p>
<a name="Fig1"></a><table width="100%">
<col align="left" valign="top" width="50%">
<col align="left" valign="top" width="50%">
<tfoot><tr><td colspan="2" align="left"><dl class="Footnote">
<dt><a name="footnote-49" href="#footnote-reference-49">*</a></dt>
<dd>The primary efficacy end point was the composite of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> from any cause or myocardial re-<span class="product-label-link" type="condition" conceptid="4206471" conceptname="Infarct">infarction</span> in the first 30 days. The overall treatment effect of enoxaparin as compared to the unfractionated heparin is shown at the bottom of the figure. For each subgroup, the circle is proportional to the number and represents the point estimate of the treatment effect and the horizontal lines represent the 95 percent confidence intervals. Fibrin-specific fibrinolytic agents included alteplase, tenecteplase and reteplase. Time to treatment indicates the time from the onset of symptoms to the administration of study drug (median, 3.2 hours).</dd>
</dl></td></tr></tfoot>
<tbody class="Headless">
<tr class="First Toprule"><td align="left" colspan="2"><span class="Bold">Figure 1. Relative Risks of and Absolute Event Rates for the Primary End Point at 30 Days in Various Subgroups <a name="footnote-reference-49" href="#footnote-49" class="Sup">*</a></span></td></tr>
<tr class="Botrule Last"><td align="center" colspan="2"><img alt="Figure 1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=53fd1302-9e1b-4e04-b06d-1a706547c388&amp;name=lovenoxnovaplus-08.jpg"></td></tr>
</tbody>
</table>
<p>The beneficial effect of enoxaparin on the primary end point observed during the first 30 days was maintained over a 12 month follow-up period (see<a href="#fig2"> Figure 2</a>).</p>
<a name="fig2"></a><table width="100%">
<col align="center" valign="top" width="100%">
<tbody class="Headless">
<tr class="First Toprule"><td align="center"><span class="Bold">Figure 2 - Kaplan-Meier plot - <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> or myocardial re-<span class="product-label-link" type="condition" conceptid="4206471" conceptname="Infarct">infarction</span> at 30 days - ITT population</span></td></tr>
<tr class="Botrule Last"><td align="center"><img alt="Figure 2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=53fd1302-9e1b-4e04-b06d-1a706547c388&amp;name=lovenoxnovaplus-09.jpg"></td></tr>
</tbody>
</table>
<p>There is a trend in favor of enoxaparin during the first 48 hours, but most of the treatment difference is attributed to a step increase in the event rate in the UFH group at 48 hours (seen in Figure 2), an effect that is more striking when comparing the event rates just prior to and just subsequent to actual times of discontinuation. These results provide evidence that UFH was effective and that it would be better if used longer than 48 hours. There is a similar increase in endpoint event rate when enoxaparin was discontinued, suggesting that it too was discontinued too soon in this study.</p>
<p>The rates of major <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhages</span> (defined as requiring 5 or more units of blood for transfusion, or  15% drop in hematocrit or clinically overt <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, including <span class="product-label-link" type="condition" conceptid="439847" conceptname="Intracranial hemorrhage">intracranial hemorrhage</span>) at 30 days were 2.1% in the enoxaparin group and 1.4% in the unfractionated heparin group. The rates of <span class="product-label-link" type="condition" conceptid="439847" conceptname="Intracranial hemorrhage">intracranial hemorrhage</span> at 30 days were 0.8% in the enoxaparin group 0.7% in the unfractionated heparin group. The 30-day rate of the composite endpoint of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, myocardial re-<span class="product-label-link" type="condition" conceptid="4206471" conceptname="Infarct">infarction</span> or ICH (a measure of net clinical benefit) was significantly lower in the enoxaparin group (10.1%) as compared to the heparin group (12.2%).</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="S16"></a><a name="section-14"></a><p></p>
<h1>16	HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">Lovenox is available in two concentrations [see<a href="#table26"> Tables 26 </a>and<a href="#table27"> 27</a>]:</p>
<a name="table26"></a><table width="80%">
<caption><span>Table 26 100 mg/mL Concentration</span></caption>
<col align="left" valign="top" width="30%">
<col align="center" valign="top" width="17%">
<col align="center" valign="top" width="20%">
<col align="center" valign="top" width="18%">
<col align="center" valign="top" width="15%">
<thead><tr class="First Last">
<th class="Rrule" align="left" valign="bottom">Dosage Unit / Strength<a name="footnote-reference-50" href="#footnote-50" class="Sup">*</a>
</th>
<th class="Rrule" align="center">Anti-Xa Activity<a name="footnote-reference-51" href="#footnote-51" class="Sup">†</a>
</th>
<th class="Rrule" align="center">Package Size (per carton)</th>
<th class="Rrule" align="center">Label Color</th>
<th align="center">NDC # 0075-</th>
</tr></thead>
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-50" href="#footnote-reference-50">*</a></dt>
<dd>Strength represents the number of milligrams of enoxaparin sodium in Water for Injection. Lovenox 30 and 40 mg prefilled syringes, and 60, 80, and 100 mg graduated prefilled syringes each contain<span class="Bold"> 10 mg enoxaparin sodium per 0.1 mL Water for Injection</span>.</dd>
<dt><a name="footnote-51" href="#footnote-reference-51">†</a></dt>
<dd>Approximate anti-Factor Xa activity based on reference to the W.H.O. First International Low Molecular Weight Heparin Reference Standard.</dd>
<dt><a name="footnote-52" href="#footnote-reference-52">‡</a></dt>
<dd>Each Lovenox prefilled syringe is for single, one-time use only and is affixed with a 27 gauge × 1/2 inch needle.</dd>
<dt><a name="footnote-53" href="#footnote-reference-53">§</a></dt>
<dd>Each Lovenox multiple-dose vial contains 15 mg benzyl alcohol per 1 mL as a preservative.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Rrule" align="left">
<span class="Bold">Prefilled Syringes</span><a name="footnote-reference-52" href="#footnote-52" class="Sup">‡</a>
</td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td align="center"></td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left">30 mg/0.3 mL</td>
<td class="Rrule" align="center">3000 IU</td>
<td class="Rrule" align="center">10 syringes</td>
<td class="Rrule" align="center">Medium Blue</td>
<td align="center">0624-31</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left">40 mg/0.4 mL</td>
<td class="Rrule" align="center">4000 IU</td>
<td class="Rrule" align="center">10 syringes</td>
<td class="Rrule" align="center">Yellow</td>
<td align="center">0620-41</td>
</tr>
<tr>
<td class="Rrule" align="left"><span class="Bold">Graduated Prefilled Syringes<a href="#footnote-52" class="Sup">‡</a></span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td align="center"></td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left">60 mg/0.6 mL</td>
<td class="Rrule" align="center">6000 IU</td>
<td class="Rrule" align="center">10 syringes</td>
<td class="Rrule" align="center">Orange</td>
<td align="center">0621-61</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left">80 mg/0.8 mL</td>
<td class="Rrule" align="center">8000 IU</td>
<td class="Rrule" align="center">10 syringes</td>
<td class="Rrule" align="center">Brown</td>
<td align="center">0622-81</td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left">100 mg/1 mL</td>
<td class="Rrule" align="center">10,000 IU</td>
<td class="Rrule" align="center">10 syringes</td>
<td class="Rrule" align="center">Black</td>
<td align="center">0623-01</td>
</tr>
<tr>
<td class="Rrule" align="left">
<span class="Bold">Multiple-Dose Vial</span><a name="footnote-reference-53" href="#footnote-53" class="Sup">§</a>
</td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td align="center"></td>
</tr>
<tr class="Last">
<td class="Rrule" align="left">300 mg/3 mL</td>
<td class="Rrule" align="center">30,000 IU</td>
<td class="Rrule" align="center">1 vial</td>
<td class="Rrule" align="center">Red</td>
<td align="center">0626-04</td>
</tr>
</tbody>
</table>
<a name="table27"></a><table width="80%">
<caption><span>Table 27 150 mg/mL Concentration</span></caption>
<col align="left" valign="top" width="30%">
<col align="center" valign="top" width="17%">
<col align="center" valign="top" width="20%">
<col align="center" valign="top" width="18%">
<col align="center" valign="top" width="15%">
<thead><tr class="First Last">
<th class="Rrule" align="left">Dosage Unit / Strength<a name="footnote-reference-54" href="#footnote-54" class="Sup">*</a>
</th>
<th class="Rrule" align="center">Anti-Xa Activity<a name="footnote-reference-55" href="#footnote-55" class="Sup">†</a>
</th>
<th class="Rrule" align="center">Package Size (per carton)</th>
<th class="Rrule" align="center">Syringe Label Color</th>
<th align="center">NDC # 0075-</th>
</tr></thead>
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-54" href="#footnote-reference-54">*</a></dt>
<dd>Strength represents the number of milligrams of enoxaparin sodium in Water for Injection. Lovenox 120 and 150 mg graduated prefilled syringes contain<span class="Bold"> 15 mg enoxaparin sodium per 0.1 mL </span>Water for Injection.</dd>
<dt><a name="footnote-55" href="#footnote-reference-55">†</a></dt>
<dd>Approximate anti-Factor Xa activity based on reference to the W.H.O. First International Low Molecular Weight Heparin Reference Standard.</dd>
<dt><a name="footnote-56" href="#footnote-reference-56">‡</a></dt>
<dd>Each Lovenox graduated prefilled syringe is for single, one-time use only and is affixed with a 27 gauge × 1/2 inch needle.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Rrule" align="left">
<span class="Bold">Graduated Prefilled Syringes</span><a name="footnote-reference-56" href="#footnote-56" class="Sup">‡</a>
</td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
<td align="center"></td>
</tr>
<tr class="Botrule">
<td class="Rrule" align="left">  120 mg / 0.8 mL</td>
<td class="Rrule" align="center">12,000 IU</td>
<td class="Rrule" align="center">10 syringes</td>
<td class="Rrule" align="center">Purple</td>
<td align="center">2912-02</td>
</tr>
<tr class="Last">
<td class="Rrule" align="left">  150 mg / 1 mL</td>
<td class="Rrule" align="center">15,000 IU</td>
<td class="Rrule" align="center">10 syringes</td>
<td class="Rrule" align="center">Navy Blue</td>
<td align="center">2915-02</td>
</tr>
</tbody>
</table>
<div class="Section" data-sectionCode="44425-7">
<a name="section-14.1"></a><p></p>
<p class="First">Store at 25°C (77°F); excursions permitted to 15–30°C (59–86°F) [see USP Controlled Room Temperature].</p>
<p>Do not store the multiple-dose vials for more than 28 days after the first use.</p>
<p><span class="Bold">Keep out of the reach of children.</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="S17"></a><a name="section-15"></a><p></p>
<h1>17	PATIENT COUNSELING INFORMATION</h1>
<p class="First">If patients have had neuraxial anesthesia or spinal puncture, and particularly, if they are taking concomitant NSAIDs, platelet inhibitors, or other anticoagulants, they should be informed to watch for signs and symptoms of spinal or <span class="product-label-link" type="condition" conceptid="4176148" conceptname="Extradural intracranial hematoma">epidural hematoma</span>, such as <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">tingling</span>, <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span> (especially in the lower limbs) and <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscular weakness</span>. If any of these symptoms occur the patient should contact his or her physician immediately.</p>
<p>Additionally, the use of aspirin and other NSAIDs may enhance the risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>. Their use should be discontinued prior to enoxaparin therapy whenever possible; if co-administration is essential, the patient's clinical and laboratory status should be closely monitored [see<span class="Italics"><a href="#S7"> Drug Interactions (7)</a></span>].</p>
<p>Patients should also be informed:</p>
<ul>
<li>of the instructions for injecting Lovenox if their therapy is to continue after discharge from the hospitals.</li>
<li>it may take them longer than usual to stop <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>.</li>
<li>they may <span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">bruise</span> and/or bleed more easily when they are treated with Lovenox.</li>
<li>they should report any unusual <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, <span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">bruising</span>, or signs of <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> (such as a <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> of dark red spots under the skin) to their physician [see <span class="Italics"><a href="#S5.1">Warnings and Precautions (5.1</a>,<a href="#S5.5"> 5.5)</a></span>].</li>
<li>to tell their physicians and dentists they are taking Lovenox and/or any other product known to affect <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> before any surgery is scheduled and before any new drug is taken [see<span class="Italics"><a href="#S5.3"> Warnings and Precautions (5.3)</a></span>].</li>
<li>to tell their physicians and dentists of all medications they are taking, including those obtained without a prescription, such as aspirin or other NSAIDs [see<span class="Italics"><a href="#S7"> Drug Interactions (7)</a></span>].</li>
</ul>
<p>sanofi-aventis U.S. LLC<br>Bridgewater, NJ 08807<br>A SANOFI COMPANY</p>
<p>Novation, the supply company of VHA and UHC, and NOVAPLUS are trademarks of Novation, LLC.</p>
<p>© 2013 sanofi-aventis U.S. LLC</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-16"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - 30mg/0.3mL Carton</span></p>
<p><span class="Italics">NDC 0075-0624-31</span></p>
<p><span class="Bold">Lovenox<span class="Sup">®</span></span><br><span class="Bold">(enoxaparin sodium injection)</span></p>
<p><span class="Bold">30mg/0.3mL</span></p>
<p><span class="Bold">Rx ONLY</span></p>
<p>SINGLE DOSE SYRINGES WITH AUTOMATIC SAFETY DEVICE</p>
<p>FOR SUBCUTANEOUS INJECTION</p>
<p><span class="Bold">Ten </span>0.3mL Syringes</p>
<p><span class="Bold">NOVAPLUS</span>™</p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 30mg/0.3mL Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=53fd1302-9e1b-4e04-b06d-1a706547c388&amp;name=lovenoxnovaplus-10.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-17"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - 40mg/0.4mL Carton</span></p>
<p><span class="Italics">NDC 0075-0620-41</span></p>
<p><span class="Bold">Lovenox<span class="Sup">®</span></span><br><span class="Bold">(enoxaparin sodium injection)</span></p>
<p><span class="Bold">40mg/0.4mL</span></p>
<p><span class="Bold">Rx ONLY</span></p>
<p>SINGLE DOSE SYRINGES WITH AUTOMATIC SAFETY DEVICE</p>
<p>FOR SUBCUTANEOUS INJECTION</p>
<p><span class="Bold">Ten </span>0.4mL Syringes</p>
<p><span class="Bold">NOVAPLUS</span>™</p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 40mg/0.4mL Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=53fd1302-9e1b-4e04-b06d-1a706547c388&amp;name=lovenoxnovaplus-11.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-18"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - 60mg/0.6mL Carton</span></p>
<p><span class="Italics">NDC 0075-0621-61</span></p>
<p><span class="Bold">Lovenox<span class="Sup">®</span></span><br><span class="Bold">(enoxaparin sodium injection)</span></p>
<p><span class="Bold">60mg/0.6mL</span></p>
<p><span class="Bold">Rx ONLY</span></p>
<p>SINGLE DOSE SYRINGES WITH AUTOMATIC SAFETY DEVICE</p>
<p>FOR SUBCUTANEOUS INJECTION</p>
<p><span class="Bold">Ten </span>0.6mL Syringes</p>
<p><span class="Bold">NOVAPLUS</span>™</p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 60mg/0.6mL Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=53fd1302-9e1b-4e04-b06d-1a706547c388&amp;name=lovenoxnovaplus-12.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-19"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - 80mg/0.8mL Carton</span></p>
<p><span class="Italics">NDC 0075-0622-81</span></p>
<p><span class="Bold">Lovenox<span class="Sup">®</span></span><br><span class="Bold">(enoxaparin sodium injection)</span></p>
<p><span class="Bold">80mg/0.8mL</span></p>
<p><span class="Bold">Rx ONLY</span></p>
<p>SINGLE DOSE SYRINGES WITH AUTOMATIC SAFETY DEVICE</p>
<p>FOR SUBCUTANEOUS INJECTION</p>
<p><span class="Bold">Ten </span>0.8mL Syringes</p>
<p><span class="Bold">NOVAPLUS</span>™</p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 80mg/0.8mL Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=53fd1302-9e1b-4e04-b06d-1a706547c388&amp;name=lovenoxnovaplus-13.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-20"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - 100mg/1mL Carton</span></p>
<p><span class="Italics">NDC 0075-0623-01</span></p>
<p><span class="Bold">Lovenox<span class="Sup">®</span></span><br><span class="Bold">(enoxaparin sodium injection)</span></p>
<p><span class="Bold">100mg/1mL</span></p>
<p><span class="Bold">Rx ONLY</span></p>
<p>SINGLE DOSE SYRINGES WITH AUTOMATIC SAFETY DEVICE</p>
<p>FOR SUBCUTANEOUS INJECTION</p>
<p><span class="Bold">Ten </span>1mL Syringes</p>
<p><span class="Bold">NOVAPLUS</span>™</p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 100mg/1mL Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=53fd1302-9e1b-4e04-b06d-1a706547c388&amp;name=lovenoxnovaplus-14.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-21"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - 300mg/3mL Carton</span></p>
<p><span class="Italics">NDC 0075-0626-04</span></p>
<p><span class="Bold">Lovenox<span class="Sup">®</span></span><br><span class="Bold">(enoxaparin sodium injection)</span></p>
<p><span class="Bold">300mg/3mL</span><br><span class="Bold">(100mg/1mL)</span></p>
<p><span class="Bold">Rx ONLY</span></p>
<p>For Subcutaneous or<br>Intravenous Injection</p>
<p>Multiple Dose Vial</p>
<p><span class="Bold">One </span>3mL Vial</p>
<p><span class="Bold">NOVAPLUS</span>™</p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 300mg/3mL Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=53fd1302-9e1b-4e04-b06d-1a706547c388&amp;name=lovenoxnovaplus-15.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-22"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - 120mg/0.8mL Carton</span></p>
<p><span class="Italics">NDC 0075-2912-02</span></p>
<p><span class="Bold">Lovenox<span class="Sup">®</span></span><br><span class="Bold">(enoxaparin sodium injection)</span></p>
<p><span class="Bold">120mg/0.8mL</span></p>
<p><span class="Bold">Rx ONLY</span></p>
<p>SINGLE DOSE SYRINGES WITH AUTOMATIC SAFETY DEVICE</p>
<p>FOR SUBCUTANEOUS INJECTION</p>
<p><span class="Bold">Ten </span>0.8mL Syringes</p>
<p><span class="Bold">NOVAPLUS</span>™</p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 120mg/0.8mL Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=53fd1302-9e1b-4e04-b06d-1a706547c388&amp;name=lovenoxnovaplus-16.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-23"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - 150mg/1mL Carton</span></p>
<p><span class="Italics">NDC 0075-2915-02</span></p>
<p><span class="Bold">Lovenox<span class="Sup">®</span></span><br><span class="Bold">(enoxaparin sodium injection)</span></p>
<p><span class="Bold">150mg/1mL</span></p>
<p><span class="Bold">Rx ONLY</span></p>
<p>SINGLE DOSE SYRINGES WITH AUTOMATIC SAFETY DEVICE</p>
<p>FOR SUBCUTANEOUS INJECTION</p>
<p><span class="Bold">Ten </span>1mL Syringes</p>
<p><span class="Bold">NOVAPLUS</span>™</p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 150mg/1mL Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=53fd1302-9e1b-4e04-b06d-1a706547c388&amp;name=lovenoxnovaplus-17.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>LOVENOX 		
					</strong><br><span class="contentTableReg">enoxaparin sodium injection</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0075-0624</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">SUBCUTANEOUS, INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>enoxaparin sodium</strong> (enoxaparin) </td>
<td class="formItem">enoxaparin sodium</td>
<td class="formItem">30 mg  in 0.3 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>water</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0075-0624-31</td>
<td class="formItem">10  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">0.3 mL in 1 SYRINGE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA020164</td>
<td class="formItem">03/12/2008</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>LOVENOX 		
					</strong><br><span class="contentTableReg">enoxaparin sodium injection</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0075-0620</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">SUBCUTANEOUS, INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>enoxaparin sodium</strong> (enoxaparin) </td>
<td class="formItem">enoxaparin sodium</td>
<td class="formItem">40 mg  in 0.4 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>water</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0075-0620-41</td>
<td class="formItem">10  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">0.4 mL in 1 SYRINGE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA020164</td>
<td class="formItem">03/12/2008</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>LOVENOX 		
					</strong><br><span class="contentTableReg">enoxaparin sodium injection</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0075-0621</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">SUBCUTANEOUS, INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>enoxaparin sodium</strong> (enoxaparin) </td>
<td class="formItem">enoxaparin sodium</td>
<td class="formItem">60 mg  in 0.6 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>water</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0075-0621-61</td>
<td class="formItem">10  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">0.6 mL in 1 SYRINGE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA020164</td>
<td class="formItem">04/17/2008</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>LOVENOX 		
					</strong><br><span class="contentTableReg">enoxaparin sodium injection</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0075-0622</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">SUBCUTANEOUS, INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>enoxaparin sodium</strong> (enoxaparin) </td>
<td class="formItem">enoxaparin sodium</td>
<td class="formItem">80 mg  in 0.8 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>water</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0075-0622-81</td>
<td class="formItem">10  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">0.8 mL in 1 SYRINGE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA020164</td>
<td class="formItem">04/21/2008</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>LOVENOX 		
					</strong><br><span class="contentTableReg">enoxaparin sodium injection</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0075-0623</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">SUBCUTANEOUS, INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>enoxaparin sodium</strong> (enoxaparin) </td>
<td class="formItem">enoxaparin sodium</td>
<td class="formItem">100 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>water</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0075-0623-01</td>
<td class="formItem">10  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">1 mL in 1 SYRINGE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA020164</td>
<td class="formItem">04/21/2008</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>LOVENOX 		
					</strong><br><span class="contentTableReg">enoxaparin sodium injection</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0075-0626</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">SUBCUTANEOUS, INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>enoxaparin sodium</strong> (enoxaparin) </td>
<td class="formItem">enoxaparin sodium</td>
<td class="formItem">300 mg  in 3 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>water</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>benzyl alcohol</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0075-0626-04</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">3 mL in 1 VIAL, MULTI-DOSE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA020164</td>
<td class="formItem">04/21/2008</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>LOVENOX 		
					</strong><br><span class="contentTableReg">enoxaparin sodium injection</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0075-2912</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">SUBCUTANEOUS, INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>enoxaparin sodium</strong> (enoxaparin) </td>
<td class="formItem">enoxaparin sodium</td>
<td class="formItem">120 mg  in 0.8 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>water</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0075-2912-02</td>
<td class="formItem">10  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">0.8 mL in 1 SYRINGE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA020164</td>
<td class="formItem">04/21/2008</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>LOVENOX 		
					</strong><br><span class="contentTableReg">enoxaparin sodium injection</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0075-2915</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">SUBCUTANEOUS, INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>enoxaparin sodium</strong> (enoxaparin) </td>
<td class="formItem">enoxaparin sodium</td>
<td class="formItem">150 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>water</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0075-2915-02</td>
<td class="formItem">10  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">1 mL in 1 SYRINGE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA020164</td>
<td class="formItem">04/21/2008</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>sanofi-aventis U.S. LLC
							(824676584)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Sanofi Winthrop Industries</td>
<td class="formItem"></td>
<td class="formItem">297730488</td>
<td class="formItem">MANUFACTURE(0075-0624, 0075-0620), ANALYSIS(0075-0624, 0075-0620), LABEL(0075-0624, 0075-0620), PACK(0075-0624, 0075-0620)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Sanofi Winthrop Industries</td>
<td class="formItem"></td>
<td class="formItem">298045688</td>
<td class="formItem">MANUFACTURE(0075-0621, 0075-0622, 0075-0623, 0075-2912, 0075-2915), ANALYSIS(0075-0621, 0075-0622, 0075-0623, 0075-2912, 0075-2915), LABEL(0075-0621, 0075-0622, 0075-0623, 0075-2912, 0075-2915), PACK(0075-0621, 0075-0622, 0075-0623, 0075-2912, 0075-2915)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">sanofi-aventis Deutschland GmbH</td>
<td class="formItem"></td>
<td class="formItem">313218430</td>
<td class="formItem">MANUFACTURE(0075-0626), ANALYSIS(0075-0626), LABEL(0075-0626), PACK(0075-0626)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 11/2013<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>2cb4222b-718d-4e8f-96ce-fc65b9a2738f</div>
<div>Set id: 53fd1302-9e1b-4e04-b06d-1a706547c388</div>
<div>Version: 8</div>
<div>Effective Time: 20131121</div>
</div>
</div> <div class="DistributorName">sanofi-aventis U.S. LLC</div></p>
</body></html>
